Final Program Programme final - CACMID...Riccarda Galioto M EETING PLANNER Gregory Tyrrell PRESIDENT CPC C O-C HAIR Heather Adam VICE PRESIDENT SCIENTIFI C PLANNING COMM ITTEE CO-C

AMMI Canada – CACMID Annual Conference Conférence annuelle April 7 – 9 avril, 2011 Le Westin Montréal

Final Program Programme final

Where Canada’s experts in clinical microbiology and infectious diseases meetPoint de rencontre des experts canadiens en microbiologie médicale et infectiologie

Association of Medical Microbiology and Infectious Disease CanadaAssociation pour la microbiologie médicale et l’infectiologie Canada

and/et

Canadian Association for Clinical Microbiology and Infectious DiseasesAssociation canadienne de microbiologie clinique et des maladies infectieuses

Information available as of time of printing

Information disponible à partir du moment de l’impression

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada.

La présente activité est une activité de formation collective agréée (section 1) au sens que lui donne le Programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada, approuvée par l’AMMI Canada.

2Welcome / Bienvenue

Dear Colleagues and Friends,We are so very pleased to welcome you to the first AMMI Canada – CACMID Annual Conference to be held in “la belle province”! What better venue could there be for combining learning, networking, and fun?This year’s conference will once again bring together students and professionals in the areas of medical/clinical microbiology, Infectious Diseases, Infection Prevention and Control, and Public Health. The collaborative efforts of the Planning and Scientific Committees have developed an informative and stimulating program drawing upon the knowledge, skills, and expertise of our own Canadian microbiology and infectious disease experts. This excellent conference program is a credit to the hard work of the planning group and the support of AMMI Canada and CACMID. It contains a well-integrated combination of plenary sessions, symposia, workshops, and poster sessions that touch on topics highly relevant to the practices of microbiology and infectious diseases, as well as the ever-popular Clinical Vignettes session. The plenary sessions deal with the challenges posed by antimicrobial resistant microorganisms and the evolving nature of HIV infection. State-of-the-Art sessions will provide insights into our understanding of the diagnosis and management of the old and the new: Clostridium difficile infection, tuberculosis and emerging viral pathogens. With our Special Lecture, we are privileged to have Dr. Horacio Arruda and Dr. Howard Njoo share their perspectives on addressing antimicrobial resistance. This premier event is made possible through the extraordinary and continued support of our conference sponsors. Be sure to see what the Exhibit Hall holds for you! Take a glimpse at the industry’s innovative products on display throughout our conference; there will be a representative to answer your questions. We hope this year’s conference combined with our social activities program, all in the incomparable city of Montréal, will provide you with a memorable and educational experience.On behalf of the Planning and Scientific Committees, we thank you for attending. Without you, this meeting would not be as great a success as it is. We look forward to sharing the next few days with you in beautiful Montréal

Chers collègues et amis,Il nous fait grand plaisir de vous accueillir à la Conférence annuelle de l’AMMI Canada – CACMID qui sera tenue, pour la première fois, dans « la belle province » ! On n’aurait choisi une meilleure ville pour offrir à nos délégués une ambiance d’apprentissage, de réseautage et de loisirs.Cette année, la Conférence annuelle rassemblera, encore une fois, les étudiants et les fournisseurs de soins de santé publique, les experts en infectiologie, en microbiologie médicale et clinique, et les professionnels de la prévention et du contrôle des infections. Les efforts de collaboration des comités de planification et scientifique ont abouti à la mise en place d’un programme informatif et stimulant, s’appuyant sur les connaissances, les compétences et l’expertise de nos professionnels canadiens en microbiologie et en infectiologie. Cet excellent programme de la conférence est le fruit du travail inlassable du comité de planification et de l’appui continu de l’AMMI Canada et de CACMID. Le programme comprend des séances plénières, des colloques, des ateliers et des sessions d’affiches qui portent sur des sujets hautement pertinents dans le domaine de la microbiologie et des maladies infectieuses, ainsi que la session populaire des Vignettes cliniques. Les séances plénières portent sur les défis posés par les micro-organismes résistants aux antimicrobiens et l’évolution des infections par le VIH. Les séances exceptionnelles donneront un aperçu sur notre compréhension du diagnostic et de la gestion des maladies actuelles et émergentes de l’infection à Clostridium difficile, la tuberculose et les nouveaux pathogènes viraux. Cette année, nous avons l’honneur d’accueillir nos conférenciers d’honneur, les Drs Horacio Arruda et Howard Njoo qui partageront leurs points de vue sur la résistance aux antimicrobiens. Cet événement de haute qualité est rendu possible grâce à l’appui extraordinaire et continu des commanditaires de la conférence. Ne manquez pas de visiter le Hall d’exposition où seront présentés les produits novateurs de notre industrie tout au long de notre conférence. Un représentant des compagnies exposantes sera disponible pour répondre à vos questions. Nous espérons que cette conférence annuelle, tenue dans l’incomparable ville de Montréal, et offrant un programme enrichissant d’activités éducatives et sociales, vous offrira une expérience des plus agréable et mémorable.Au nom des comités de planification et scientifique, nous vous remercions d’avoir participé à notre conférence. Sans vous, cet événement n’aurait pas pu être un grand succès. Nous nous réjouissons de passer les prochains jours avec vous dans la belle ville de Montréal.

Conférence annuelle AMMI Canada – CACMID Annual Conference

2

Lynn Johnston Gregory TyrrellPRESIDENT, AMMI CANADA PRESIDENT, CACMIDPRÉSIDENTE DE L’AMMI CANADA PRÉSIDENT DE CACMID

Objectives

The 2011 Annual Conference is designed to address the broad needs of health care professionals specializing in the areas of clinical and medical microbiology and infectious diseases: laboratory, clinical (adult and paediatric), public health and infection prevention and control issues. The program includes a selection of symposia, plenary sessions, state of the art clinical lectures, clinical vignettes and presentations, both in short oral and poster formats. These formats will allow ample time for presentation of innovative scientific research with practical applications on contemporary issues. The presenters include world-renowned experts, microbiologists and infectious diseases specialists across Canada, students/trainees, and laboratory technologists.

In addition, this year’s conference will provide opportunities to network and share current information and ideas. It is where Canada’s experts in clinical microbiology and infectious diseases meet.

The 2011 Annual Conference offers an educational forum that will address:• New findings from basic research in clinical microbiology;• Updates on diagnostics and therapeutics;• The most recent trends in prevention and control of infections;• New findings on pathogenesis and epidemiology of established

and newly recognized microbes;• Analysis of increasing antimicrobial resistance in

diverse pathogens;

• The public health impact of infectious diseases.


3

Welcome from Montréal Tourism

Committees 4General Information 6Accreditation 6Hotel Information 7Exhibits 8Education Grants 8Montréal 9Program at a Glance 10AMMI Canada – CACMID Special Lecture, Awards Presentations and Clinical Vignettes 12Integrated Symposia 12Association, Committee & Other Group Meetings 14CCM Workshop 15Quality Management (QM) Seminar 15Educational Program 16Poster Presentations and Student Poster Presentations 28Closing Dinner 36Authors Index 37Speaker Bios 40Exhibitor Directory 44Exhibition Overview 52Floor Plans 54Sponsors 56

Table of Contents

On behalf of the Montréal tourism industry, welcome to the first AMMI Canada – CACMID Annual Conference held in Montréal. Home to a vibrant science sector and numerous scientific associations, our city is very proud to be hosting your event.

Montréal’s unique blend of European charm and North American energy has given rise to its reputation as one of the most exciting, open and inspirational destinations in the world. We invite you to celebrate Montréal in all its dimensions, from its gourmet dining and celebrated nightlife to its rich history and lively cultural celebrations. You will discover that Montrealers are not only passionate about life, but also about greeting visitors with a warm welcome.

We invite you to discover and enjoy our safe downtown, historic Old Montréal, as well as our exquisite gastronomy, unique architecture, and most of all, our “joie de vivre”. We are thrilled to have you with us.

Bienvenue!

Sincerely,

The Honourable Charles Lapointe, P.C.PRESIDENT AND CHIEF EXECUTIVE OFFICER

TOURISME MONTRÉAL

44

Lynn Johnston PRESIDENT CPC CO-CHAIR

Mark Joffe PRESIDENT ELECT

Kevin Forward SCIENTIFIC PLANNING COMMITTEE CO-CHAIR

Gerald Evans PAST PRESIDENT

Coleman Rotstein SPONSORSHIP COMMITTEE CO-CHAIR

Mel Krajden CO-TREASURER

Brett Filson EXECUTIVE DIRECTOR

Riccarda Galioto MEETING PLANNER

Gregory Tyrrell PRESIDENT CPC CO-CHAIR

Heather Adam VICE PRESIDENT SCIENTIFIC PLANNING COMMITTEE CO-CHAIR

Karam Ramotar PAST PRESIDENT

Julie Carson SPONSORSHIP COMMITTEE CO-CHAIR

Matthew Gilmour CO-TREASURER

Tim Karnauchow MEETING SECRETARY ABSTRACT CHAIR

Central Planning Committee (CPC)Comité de planification

Scientific Planning Committee (SPC) Comité scientifique

AMMI CanadaKevin Forward, CO-CHAIR

Vikas ChaubeyIsabelle ChiuGerald EvansSarah ForgieTodd HatchetteMark JoffeMatthew OughtonDavid PatrickSusan Poutanen

CACMIDHeather Adam, CO-CHAIR

Julie CarsonSuzanne E. DaleMatthew GilmourJonathan GubbayLinda HoangTim KarnauchowDuncan Webster

AMMI Canada CouncilPresidentLynn Johnston (Halifax, NS)Presdient - Elect Mark Joffe (Edmonton, AB)Past President Gerald Evans (Kingston, ON)Treasurer Mel Krajden (Vancouver, BC)Secreatry Sarah Forgie (Edmonton, AB)Medical Microbiology Section Head Michelle Alfa (Winnipeg, MB)Infectious Disease Section Head Neil Vivek Rau (Oakville, ON)CouncillorsMarissa Becker (Winnipeg, MB)Cécile Tremblay (Montréal, QC)Sylvie Champagne (Vancouver, BC)Todd Hatchette (Halifax, NS)Michael Libman (Montréal, QC)Anne Opavsky (Toronto, ON)

EX-OFFICIO MEMBERSGrants and Awards Committee ChairChristina Greenaway (Montréal, QC)Program Planning Committee Co-Chair Kevin Forward (Halifax, NS)Associate Committee Chair Vikas Chaubey (Calgary, AB)

Committees


Tim Karnauchow (Ottawa, ON) - CHAIR

Heather Adam (Winnipeg, MB)

Sylvie Champagne (Vancouver, BC)

Isabelle Chiu (Edmonton, AB)

Suzanne Dale (Hamilton, ON)

Marc Desjardins (Ottawa, ON)

Gerald Evans (Kingston, ON)

David Fisman (Toronto, ON)

Sarah Forgie (Edmonton, AB)

Matthew Gilmour (Winnipeg, MB)

Jonathan Gubbay (Toronto, ON)

Linda Hoang (Vancouver, BC)

Mark Joffe (Edmonton, AB)

Lynn Johnston (Halifax, NS)

Anne Opavsky (Toronto, ON)

Karam Ramotar (Ottawa, ON)

Neil Rau (Oakville, ON)

Susan Richardson (Toronto, ON)

Joan Robinson (Edmonton, AB)

Gregory Tyrrell (Edmonton, AB)

Collaborating Societies

Alberta Society for Infectious Diseases (ASID)

Association des médecins microbiologistes infectiologues du Québec (AMMIQ)

British Columbia Association of Medical Microbiologists (BCAMM)

Canadian Association for HIV Research (CAHR)

Canadian College of Microbiologists (CCM)

Canadian Society for Medical Laboratory Science (CSMLS)

Canadian Society of Hospital Pharmacists (CSHP)

Canadian Society of Microbiologists (CSM)

Community & Hospital Infection Control Association - Canada (CHICA-Canada)

Infectious Diseases Society of America (IDSA)

Pan American Society for Clinical Virology

Society of Healthcare Epidemiology of America (SHEA)


5Committees

CACMID BoardPresident Gregory Tyrrell (Edmonton, AB)Past President Karam Ramotar (Ottawa, ON)Vice President Heather Adam (Winnipeg, MB)Secretary Treasurer Matthew Gilmour (Winnipeg, MB)Meeting Secretary/Councillor Tim Karnauchow (Ottawa, ON)CouncillorsJonathan Gubbay (Toronto, ON)Suzanne Dale (Hamilton, ON)Julie Carson (Calgary, AB)Linda Hoang (Vancouver, BC)Duncan Webster (Saint John, NB)

Abstract Review Committee


6

Scientific Committees, AMMI Canada and CACMID or their agents are not liable for any loss or inconvenience caused as a result of such cancellation, and delegates are therefore advised to take out their own travel insurance and extend their policy for personal possessions as the annual conference does not cover individuals against cancellations of bookings or theft or damage of belongings.

HANDOUTSHandouts will not be available at the Conference. Following conference, presentations approved by speakers for posting will be uploaded to both the AMMI Canada and CACMID web sites.

LOST AND FOUNDItems may be left at the Registration Desk.

MESSAGES AND CONFERENCE UPDATESA message board will be available by the Registration Desk for posting messages for other delegates and to announce last-minute program changes.

General Information

CONFERENCE EVALUATIONThe conference evaluation will be sent after conference via email to all registered delegates. It will be a short online survey.

CD-ROM of AbstractsAll presented abstracts are available to participants on CD-ROM only. There will be no printed abstract book.

DISCLAIMERThe Central Planning and Scientific Committees will make every effort to present the Program as published and printed. However, the Central Planning and Scientific Committees, AMMI Canada and CACMID or their agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the annual conference, for any cause beyond their reasonable control. The above-men-tioned are not liable for any loss or inconvenience caused as a result of such alteration.

In the event of cancellation of the annual conference, all pre-paid fees will be refunded in full, however the Central Planning and

Accreditation – CME CreditsA. For specialists certified with the Royal College of

Physicians and Surgeons of Canada (RCPSC)“This education event is approved as an Accredited Group Learning Activity; section 1 as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada”.B. For specialists certified with the American

Medical Association (AMA)“Through an agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada the Association of Medical Microbiology and Infectious Disease (AMMI) Canada designated this live educational activity, the AMMI Canada – CACMID Annual Conference 2011, for AMA PRA category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.”

Please indicate your AMA ID number when registering.

C. For Fellows and Specialists of the Canadian College of Microbiology and Diplomats of the American Board of Medical Microbiology

The Canadian College of Microbiology accredits the AMMI Canada - CACMID annual conference for CE credits. Certificates of continuing education activity are available through the CCM for documentation of attendance and maintenance of certification. A 1 hour educational activity is equivalent to 1 CE credit. Program evaluation forms and record of CE activity can be obtained and returned, once completed, at the conference registration desk or through the CCM web site (http://www.ccm.ca) following the conference. Workshops, plenary sessions, state of the art clinical lectures, and integrated symposia are accredited activities; however, the oral presentations are not.

MAINPORT – Transfer of HoursThe Royal College of Physicians and Surgeons of Canada allows for attendance data of Section 1, Group Learning activities to be transferred directly into participants’ MAINPORT accounts. In order to take advantage of the MAINPORT Transfer of Hours, simply indicate your RCPSC ID number when registering.


7

REGISTRATION DESK (9th floor – Cloakroom)

Wednesday April 6 1600 – 1900

Thursday April 7 0700 – 1700

Friday April 8 0700 – 1700

Saturday April 9 0730 – 1700

SPEAKER READY ROOM (3rd floor – Bonsecours Room)




Saturday April 9 0700 – 1700 Internet Café – 3rd FloorThursday April 7 to Saturday April 9Sponsored by Abbott

Hotel InformationLe Westin Montréal is the triumphant result of the restoration of three heritage buildings dating back to the late 1800’s, combined with a new ultra-modern 22-storey hotel tower. On this historical site, the presses of Montréal’s The Gazette newspaper rolled for more than 100 years.

Steps away from the hotel, the cobblestone streets of Old Montréal pave the way for an exploration of the restaurants, galleries, boutiques and notable sites that epitomize Montréal’s history and joie de vivre. Old Montréal is everything old, and everything new.

Le Westin Montréal270 St. Antoine West Montréal, Québec H2Y 0A3 Toll Free: 1-877-961-8111 Fax: (514) 380-3333 www.westinmontreal.com

Concierge ServiceA Concierge Service will be offered for the AMMI Canada – CACMID Annual Conference delegates and families. Well trained and knowledgeable staff will help you enjoy the perfect conference experience in the beautiful city of Montréal and surrounding areas. Services include:

• helping you find a perfect restaurant;

• helping you find information on famous tourist attractions;

• providing maps and vacation guides;

• outlining great shopping, or outdoor adventures for the whole family to enjoy.

To find out what Montréal holds in store for you, visit Tourisme Montréal at http://www.tourisme-montreal.org/.

Concierge Service Hours (9th floor – Cloakroom)




Saturday April 9 1030 – 1400

General Information

88

AMMI Canada Education Grants (For Associate members ONLY)

CACMID Education Grants (For Technical staff ONLY)

EligibilityApplicants must be microbiology laboratory technologists or technicians and active members of CACMID. Each applicant is eligible for only one grant. To be eligible, the applicant must be the presenting author in an oral or poster session at the AMMI Canada – CACMID Annual Conference in Montréal 2011.

ApplicationAn education grant application form will be available at the registration desk during the conference or it can be downloaded from the CACMID website (www.cacmid.ca). This form can be completed during the conference and deposited at the registration desk, or completed after the conference and mailed to the CACMID Secretary Treasurer (www.cacmid.ca/contact-us/).

$ 250 for Associates attending from Québec

$ 500 for Associates attending from Ontario, Manitoba, PEI, New Brunswick, Nova Scotia, and Newfoundland

$ 750 for Associates attending from Alberta, Saskatchewan, and British Columbia

$ 1,000 for Associates attending from NWT, Yukon, Nunavut, and International

NB: Technical staff attending from the city of Montréalare ineligible for grants.

EligibilityIn order to apply for a grant, you must be an AMMI Canada Associate member in good standing. You must register for the full conference, pay the registration fee, sign-in on site and submit an Education Grant form.

ApplicationThe forms will be available at the registration desk during the conference. The form can be completed during the conference and deposited, at the registration desk or completed after the conference and sent to the AMMI Canada Secretariat by mail or email.

$ 250 for Associates attending from Québec

$ 500 for Associates attending from Ontario, Manitoba, PEI, Newfoundland, New Brunswick, Nova Scotia, Saskatchewan, Alberta and Nunavut

$ 750 for Associates attending from British Columbia, NWT, Yukon, USA

NB: Associates attending from the city of Montréal are ineligible for grants.

Exhibits — 8th Floor

The AMMI Canada – CACMID Annual Conference has received tremendous support from our exhibiting companies and, as a result, the exhibit hall is full. We encourage you to visit the exhibit hall, to discover the leading edge of business and research in the fields of medical microbiology, infectious diseas-es, medicine, pharmaceuticals and diagnostics.

Take advantage of no programming between 1030 and 1200 to reconnect with industry colleagues.

Morning breaks and lunches will be served in the exhibit hall on Thursday and Friday.


EXHIBIT HOURS• EXHIBIT HALL CLOSES AT 1400 EACH DAY

Thursday April 71030 – 1400 1700 – 1900 (Welcome Reception)

Friday April 81030 – 1400


9

Relive the romance of days gone by amidst Old Montréal’s cobblestone streets and 18th- and 19th-century stone buildings, taking time to gaze in awe at Notre-Dame Basilica.

Amble towards the present through Montréal’s new jewel of urban design—the Quartier International—and beyond to experience the downtown’s eclectic mix of old and new: striking skyscrapers, heritage buildings, sleek cafés, designer boutiques and art galleries plus architectural innovations such as Place Ville-Marie and the Underground Pedestrian Network set the scene for Montréal’s cosmopolitan vibe.

The futuristic constructions such as Expo 67’s geodesic Biosphère, the Casino de Montréal, Habitat 67’s building-block apartments and the Olympic Stadium are all testament to Montréal’s avant-garde vision.

Mount Royal, with its stately greystone buildings and Victorian-style mansions stands tall, while St. Joseph’s Oratory watches over the city from its imposing perch.

Finally, Montréal’s neighbourhoods. Its signature wrought-iron staircases, the “plexes” of many configurations (du, tri, four and five), plus the cultural touches of its diverse communities, reveal the true nature of this tremendous city.

Welcome Reception Date: Thursday, April 7Time: 1700 – 1900Location: Exhibit Hall 8th Floor Le Westin Montréal

Montréal

Only in Montréal does a simple stroll seem like time travel: you go back in time or leap to the future with every step. With memories of New France swirling amongst ultramodern construction, it’s no wonder that Montréal was the first North American city to be named a UNESCO City of Design (2006).

Don’t miss this opportunity to network with colleagues and friends for a glass of wine and hors d’oeuvres.


10

9

76

8

Program at a Glance

0700

WednesdayApril 6

ThursdayApril 7

FridayApril 8

SaturdayApril 9

0800 0900 1000 1100 1200

1230 – 1745 Trainees Day Ville-Marie Room (9th floor)

0645 – 0800 AMMI Canada AGM/Sections Meetings Ville Marie B (9th floor)

0645 – 0800 CACMID AGM Ville Marie B (9th floor)

0800 -1030 PLENARY – Update of HIV Montreal Ballroom (11th floor)

1030 – 1130 CCM AGM Ville Marie B Room (9th floor)

1030 – 1400 Tourism Montreal Concierge Service (9th floor)

1045 – 1145 Oral Presentations Session I Ville Marie A (9th floor) Session J St Antoine A (9th floor) Session K Ville Marie B (9th floor) Session L St Antoine B (9th floor)


1030 – 1400 Exhibits Hall Opens (8th floor)

1030 – 1400 Clinical Vignette Poster Viewing McGill Room (8th floor)

1030 – 1400 Student Poster Viewing McGill and Palais Rooms (8th floor)

1030 – 1400 Poster Viewing McGill, Palais, Viger, Ramezay, St. Paul (8th floor)

1030 – 1200 Posters – Presenters at Posters McGill, Palais, Viger, Ramezay, St. Paul (8th floor)

0800 – 1030 PLENARY – Emerging problems in multi-drug resistance Montreal Ballroom (11th floor)

0800 – 1030 PLENARY – Review of clinical microbiology and infectious diseases: what’s new and what’s hot? Room: Montreal Ballroom (11th floor)

0800 – 1200 CCM Workshop Ville-Marie Room (9th floor)

0700 – 1700 Registration Cloakroom (9th floor)

1100 – 1200 World Health Day News Conference St Antoine B Room (9th floor)

1130 – 1400 Royal College Specialty Committee in Medical Microbiology Meeting St. Sulpice Room (3rd floor)

0800 – 1700 AMMI Canada Council Meeting St. Sulpice Room (3rd floor)

1200 – 1400 AMMI Canada – Guidelines Youville Room (3rd floor) Committee Meeting1200 – 1400 Integrated Symposium hosted by Fortifications Ballroom (9th floor) Pfizer, infectious diseases

1200 – 1300 Lunch in Exhibit Hall (8th floor)

0730 – 1700 Registration (9th floor)

0700 – 1700 Speaker Ready Room Bonsecours Room (3rd floor)




1030 – 1400 Tourism Montreal Concierge Service (9th floor)1030 – 1400 Exhibits Hall Opens (8th floor)


1030 – 1200 Student Posters – Presenters at Posters and Judging McGill and Palais Rooms (8th floor)



1200 – 1400 PICNIC Meeting Notre Dame Room (3rd floor)

1200 – 1400 AMMI Canada Communications and PR Committee Meeting Youville Room (3rd floor)

1200 – 1400 Delegate Lunch Foyer (9th floor)

1200 – 1400 Integrated Symposium hosted by Merck Fortifications Ballroom

1130 – 1400 Royal College SpecialtyCommittee in Infectious Diseases Meeting St. Sulpice Room (3rd floor)

1130 – 1400 CJID&MM Editorial Board Meeting Youville Room (3rd floor)

1130 – 1400 AMMI Canada – Antimicrobial Stewardship and Resistance Committee Meeting Notre Dame Room (3rd floor)

1200 – 1300 National Microbiology Diagnostics Users Group Meeting Ville Marie A Room (9th floor)


1200 – 1400 Industry Symposium hosted by Novartis Fortifications Ballroom (9th floor)


11Program at a Glance

1300 1400 1500 1600 1700 1800 1900


1230 – 1745 Trainees Day Ville-Marie Room (9th floor)



1400 – 1500 Exhibitor Debrief (Pharma) Le Moyne Room (8th floor)

1415 – 1515 State of the Art Clinical Lecture Montreal Ballroom (11th floor)




1400 – 1700 CCM Board Meeting Notre Dame Room (3rd floor)



0700 – 1700 Registration Cloakroom (9th floor)

1130 – 1400 Royal College Specialty Committee in Medical Microbiology Meeting St. Sulpice Room (3rd floor)

0800 – 1700 AMMI Canada Council Meeting St. Sulpice Room (3rd floor)

1300 – 1700 QM Seminar St Antoine Room (9th floor)

1700 – 1900 Welcome Reception in Exhibit Hall (8th floor)

1530 – 1700 Oral Presentations Session A Ville Marie A (9th floor)

1530 – 1700 Oral Presentations Session E Ville Marie A (9th floor)

1530 – 1700 Oral Presentations Session G Ville Marie B (9th floor)

1530 – 1700 Oral Presentations Session F St. Antoine A (9th floor)

1530 – 1700 Oral Presentations Session H St. Antoine B (9th floor)

1715 – 1915 Integrated Symposium hosted by Pfizer, vaccines Fortifications Ballroom (9th floor)

1530 – 1715 Oral Presentations Session B St. Antoine A (9th floor)

1400 – 1500 Exhibitor Debrief (Diagnostic) Le Moyne Room (8th floor)


1200 – 1400 AMMI Canada – Guidelines Youville Room (3rd floor) Committee Meeting1200 – 1400 Integrated Symposium hosted by Fortifications Ballroom (9th floor) Pfizer, infectious diseases











1200 – 1400 PICNIC Meeting Notre Dame Room (3rd floor)

1200 – 1400 AMMI Canada Communications and PR Committee Meeting Youville Room (3rd floor)

1200 – 1400 Delegate Lunch Foyer (9th floor)

1200 – 1400 Integrated Symposium hosted by Merck Fortifications Ballroom


1530 -1800 Special Lecture, Awards Presentations and Clinical Vignettes Montreal Ballroom (11th floor)

1845 – 1900 Bus transfers to Museum of Fine Arts1900 – 2200 Closing Dinner Museum of Fine Arts

1130 – 1400 Royal College SpecialtyCommittee in Infectious Diseases Meeting St. Sulpice Room (3rd floor)

1130 – 1400 CJID&MM Editorial Board Meeting Youville Room (3rd floor)

1130 – 1400 AMMI Canada – Antimicrobial Stewardship and Resistance Committee Meeting Notre Dame Room (3rd floor)

1200 – 1300 National Microbiology Diagnostics Users Group Meeting Ville Marie A Room (9th floor)


1200 – 1400 Industry Symposium hosted by Novartis Fortifications Ballroom (9th floor)

1730 – 1830 AMMI Canada Associate Committee Meeting Ville Marie Room (9th floor)

1730 – 1900 CACMID Board Meeting Youville Room (3rd floor)


1530 – 1700 Oral Presentations Session C Ville Marie B (9th floor)

1530 – 1700 Oral Presentations Session D St. Antoine B (9th floor)


12

Saturday April 9 Montreal Ballroom – 11th Floor

Necessity as the Mother of StewardshipResistance and Surveillance: Examples from Québec, and Directions for CanadaModerator: Lynora Saxinger (Edmonton, AB)

This Special Lecture on Stewardship, Resistance and Surveillance focuses on the public health implications of resistance and antimicrobial overuse, and will highlight “good practice” examples and shared challenges experienced by our host province, Québec. Moving to a national perspective, we will hear a discussion of where we are, and where we need to go in surveillance of antimicrobial resistance and antimicrobial utilization, and the way forward in planning a national coordinated response.

The Québec ExperienceHoracio Arruda, Deputy Chief Medical Officer of Health, Ministère de la Santé et des Services Sociaux du Québec

• To describe surveillance for C. difficile and other antibiotic resistance organisms in Québec, including the development of the current surveillance in a historical context.

• To reflect on reasons why antibiotic utilization is lower in Québec than in other areas of Canada, and share challenges and successes in antimicrobial stewardship.

• To describe any formal programs of measurement of antibiotic utilization in Québec communities or hospitals.

Future Directions in CanadaHoward Njoo, Director General, Centre for Communicable Diseases and Infection Control Branch, Public Health Agency of Canada

• To reflect on recent national experiences in Antimicrobial Resistance (AMR) issues.

• To describe the findings of the recent PHAC Gap Analysis in AMR in Canada.

• To discuss the current state and desired future of integrated Canadian infectious diseases resistance surveillance and control, and antimicrobial stewardship.

• To respond to the challenges enumerated by the WHO for World Health Day on Antimicrobial Resistance (April 7, 2010).

AMMI Canada – CACMID Special Lecture, Awards Presentations and Clinical Vignettes

Sponsored by:

SAVE THE DATE

Integrated Symposia co-developed with AMMI Canada

Thursday April 7, 1200 – 1400 Fortifications Ballroom – 9th Floor

Hosted by Pfizer (Infectious Diseases)

Friday April 8, 1200 – 1400 Fortifications Ballroom – 9th Floor

Hosted by NovartisFriday April 8, 1715 – 1915 Fortifications Ballroom – 9th Floor

Hosted by Pfizer (Vaccines)

Saturday April 9, 1200 – 1400 Fortifications Ballroom – 9th Floor

Hosted by Merck

AMMI Canada – CACMID Annual Conference 2012

Vancouver, BC MAY 3 – 5

Sheraton Vancouver Wall Centre


13

Awards PresentationsMasters of Ceremony:Lynn Johnston, AMMI Canada PresidentGregory Tyrrell, CACMID President

2011 AMMI Canada / Astellas Post Residency FellowshipDr. Cecilia Costiniuk is the recipient of this year’s fellowship. Dr. Costiniuk is presented a one year fellowship for her research proposal entitled: “Oncolytic viruses as a potential approach to eliminate the HIV reservoir”.Presenting the award: Barbara Reynolds, Director of Marketing

ASTELLAS PHARMA CANADA, INC.

2011 AMMI Canada / Pfizer Post Residency FellowshipDr. Valérie Martel-Laferrière is the recipient of this year’s fellowship. Dr. Martel-Laferrière is presented a one year fellowship for her research proposal entitled: “Effect of Rifaximin on the Evolution of Liver Fibrosis in HIV Positive Individuals”.Presenting the award: Tina Graves, Brand Manager

PFIZER CANADA, INC.

2010 CJIDMM Trainee Review Article AwardDr. Victor Leung is the recipient of this award. Dr. Leung is pre-sented with the award for his article entitled: Detection of sca-bies: a systematic review of diagnostic methods. Presenting the award: Kevin Forward, Associate Editor, CJIDMM

2010 AMMI Canada Distinguished Service AwardDr. Michel Laverdière is the recipient of this award. Dr. Laverdière is presented this prestigious award for his many years of services to both CIDS and AMMI Canada. Dr. Laverdière served as President- elect, President and Past President of AMMI Canada during its first six years of life. He has also been a public advocate of AMMI Canada for many years and was instrumental in obtaining funding for the first two post-residency fellowships being awarded tonight.Presenting the award: Lynn Johnston, AMMI Canada President

2010 AMMI Canada Lifetime Achievement AwardDr. Alan Ronald is the recipient of this award. Dr. Ronald is presented this award for his many years of service to the field of infectious disease. He established ID as a sub-specialty and trained the majority of academic ID physicians working today in Canada. As a result of his vision, the HIV project was established in Kenya, a Kenya/Manitoba partnership that has produced high quality HIV research for over 20 years now. Dr. Ronald continues in his retirement to be highly productive, advocating for important issues on a global level. Presenting the award: Lynn Johnston, AMMI Canada President

2011 STUDENT POSTER AWARDSThe poster awards are presented to the four best poster presentations by students attending the annual conference as per the following:

Association of Medical Microbiology and Infectious Disease (AMMI) Canada Poster AwardPresenting the award: Lynn Johnston, AMMI Canada President

Canadian Association For Clinical Microbiology and Infectious Disease (CACMID) Poster AwardPresenting the award: Gregory Tyrrell, CACMID President

Canadian College of Microbiologists (CCM) Poster AwardPresenting the award: Paul Levett, CCM President

Canadian College of Microbiologists (CCM) Award in Environmental Microbiology Poster AwardPresenting the award: Paul Levett, CCM President

AMMI Canada – CACMID Special Lecture, Awards Presentations and Clinical Vignettes

The Canadian College of Microbiologists (CCM) Distinguished Microbiologist AwardThe 2011 award is presented to Dr. Lorne Babiuk. This award is given in recognition of outstanding professional contributions to the field of microbiology in Canada in the areas of research, teaching and involvement in the Canadian College of Microbiologists and other professional societies.Presenting the award: Paul Levett, CCM President

Dr. Lindsay E. Nicolle Editorial AwardThis award is given annually in honour of Dr. Lindsay E. Nicolle, the Founding Editor-in-Chief of The Canadian Journal of Infectious Diseases & Medical Microbiology (formerly The Canadian Journal of Infectious Diseases). This Award is given to an individual who has made a significant contribution to Infectious Diseases and Medical Microbiology as demonstrated by the impact of their original research published in The Canadian Journal of Infectious Diseases & Medical Microbiology.Presenting the award: Robert Kalina, President of Pulsus Group

Dr. Susan King AwardThis award is to be given annually to the best abstract by a trainee on a pediatric topic. It is presented in honour of Dr. Susan King. Funds for this award are generously provided by the PICNIC team and The Hospital for Sick Children (Division of Infectious Diseases).Presenting the award: Upton Allen


14

Are you a member?To join AMMI Canada please contact:Sarah Forgie, Secretaryc/o Kimberley Wannamaker, MEMBERSHIP COORDINATOR

101-298 Elgin Street Ottawa, ON K2P 1M3Tel: 1-866-467-1215 (toll free) (613) 260-3233 ext 103 Fax: (613) 260-3235 [email protected]

For more information on AMMI Canada visit: www.ammi.ca

To join CACMID please contact:Matthew W. Gilmour, SECRETARY TREASURER

CHIEF, ENTERIC DISEASES, NATIONAL MICROBIOLOGY LABORATORY

c/o PUBLIC HEALTH AGENCY OF CANADA

1015 Arlington Street Winnipeg, MB R3E 2R2

Tel: (204) 784-5920 Fax: (204) 789-5012 [email protected] more information on CACMID visit: www.cacmid.ca

Association, Committee & Other Group Meetings

Wednesday April 60800 – 1700 AMMI Canada Council Meeting

Room: St. Sulpice (3rd floor) Chair: Lynn Johnston1400 – 1700 CCM Board Meeting

Room: Notre Dame (3rd floor) Chair: Linda Chui1730 – 1830 AMMI Canada Associate Committee Meeting

Room: Ville Marie (9th floor) Chair: Vikas Chaubey1730 – 1900 CACMID Board Meeting

Room: Youville (3rd floor) Chair: Gregory Tyrrell

Thursday April 70645 – 0800 AMMI Canada – Annual General Meeting and

Sections MeetingRoom: Ville Marie B (9th floor)

Chair: Lynn Johnston1100 – 1200 World Health Day News Conference

Room: St-Antoine B (9th floor) Emcee: Margaret Fast

1130 – 1400 Royal College Specialty Committee in Medical Microbiology MeetingRoom: St Sulpice (3rd floor)

Chair: Marie Louie1200 - 1400 AMMI Canada – Guidelines Meeting

Room: Youville (3rd floor) Chair: Ethan Rubinstein

Friday April 80645 – 0800 CACMID – Annual General Meeting

Room: Ville Marie B (9th floor) Chair: Gregory Tyrrell1030 – 1130 CCM Annual General Meeting

Room: Ville Marie B (9th floor) Chair: Linda Chui1130 – 1400 Royal College Specialty Committee in

Infectious Diseases MeetingRoom: St. Sulpice (9th floor)

Chair: Lynn Johnston1130 – 1400 CJID&MM Editorial Board Meeting

Room: Youville (3rd floor) Chair: John Conly1130 – 1400 AMMI Canada – Antimicrobial Stewardship and

Resistance Committee MeetingRoom: Notre Dame (3rd floor)

Chair: Lynora Saxinger1200 – 1300 National Microbiology Diagnostics Users Group

(NMG) MeetingRoom: Ville Mare B (9th floor)

Chair: Alan McNabb1400 – 1500 Exhibitor Debrief (Pharma)

Room: Le Moyne (8th floor) Chair: Ron Rosenes

Saturday April 91200 – 1400 PICNIC Meeting

Room: Notre Dame (3rd floor) Chair: Upton Allen1200 – 1400 AMMI Canada – Communications and PR

Committee Meeting Room: Youville (3rd floor)

Chair: Gerald Evans


15

CCM WorkshopWednesday, April 6, 2011Le Westin MontréalRoom: Ville Marie (9th floor)

Time: 0800 – 1200 0800 – 0830 Breakfast

Title: Breakpoint - Counterpoint. Defining a Canadian Perspective Chair: Jeff Fuller

Cost: $70 plus 5% GSTObjectives: 1. To review and debate the approach to susceptibility

breakpoint assignment. 2. To discuss the utility and development of a national

consensus on antimicrobial susceptibility reporting in Canada.

Robert Rennie – Alphabet soup – MIC, ECV, PKPD, and RCT

Gunnar Kahlmeter – The EUCAST Perspective

L. Barth Reller – The CLSI Perspective

Panel Discussion with the Audience

Participants will receive a statement for four CEU in Continuing Professional Development (Category 1, Accredited Group Interactive Learning Activities).

Information on the requirements for membership in the Canadian College of Microbiologists is available at www.ccm.ca.

Sponsors: Abbott Affinity Diagnostics

Alere Astellas

Bayer bioMerieux

CACMID Merck

Oxoid Pfizer

Sepracor Siemens

Quality Management (QM) SeminarWednesday, April 6, 2011Le Westin MontréalRoom: St. Antoine (9th floor)

Time: 1300 – 1700

Cost: $80 plus 5% GSTTitle: Communicating QualityTheme: If nobody talks about Quality then it probably does not exist.

Improving Quality in the modern laboratory requires engagement and conversation. The seminar will address the spectrum of communication through daily awareness, newsletters, websites, blogs, and courses. All are important because they promote discussion, and provoke thought and action.

Objectives:1. Learn the relationship between culture and quality.

2. Understand the linkages and opportunities with conventional, electronic, and social network

3. Quality communication at both the micro-and macro system levels.

4. Become aware of Quality Education opportunities.

5. Understanding Quality communication better: what works and what does not.

Michael Noble (Program Office for Laboratory Quality Management – University of British Columbia) Connecting the communications dots

Julie Coffey (Quality Management Program – Laboratory Services, ON) Quality Education

Robert Michel (Dark Report, San Antonio Texas) Developing the international Quality megacenter

Sara Garcha (Fraser Heath Authority, BC) Impact of Culture on Quality and Communication

This seminar is a must see for anyone charged with developing and promoting a quality system in their own laboratory, or as is happening more and more, a network of laboratory sites.

The CCM Workshop and QM Seminar are the perfect complements to the AMMI Canada – CACMID Annual Conference. Both are optional and open to everyone interested, even if they are not attending the conference.

To register for these activities please visit either www.ammi.ca or www.cacmid.ca and follow the directions to the annual conference sections – online registration form.


16

Caroline Quach – (Montreal, QC) Objectives:

• Outline advantages of academic practice;• Identify challenges of academic practice;• Present my personal experience. Roundtable Discussion Question and Answer period1535-1545 BREAK1545-1650 Contract Negotiations & How to

Market Oneself William Ciccotelli (Hamilton, ON) Neil Rau (Oakville, ON) Matthew Oughton (Montreal, QC)

Objectives:• What you can do to improve your chances of

getting a job.• What can you expect when negotiating a contract?• What should you ask in your negotiations?• Personal Experiences Roundtable discussion Question and Answer period1650-1700 BREAK1700-1745 Mapping the Boundaries of

Physician-Industry Interaction: A Survival Guide

Gerald Evans (Kingston, ON) Objectives:

• Identify the important boundaries in their interactions with pharmaceutical and other industry representatives.

• Recall the guidelines that exist that define professionalism between physicians and for-profit industry.

• Recognize methods used by industry to influence your professional judgement.

1300 – 1700 Quality Management (QM) Seminar – Communicating Quality(St Antoine – 9th floor)

1400 – 1700 CCM Board Meeting(Notre Dame – 3rd floor)

1730 – 1830 AMMI Canada Associate Committee Meeting(Ville Marie – 9th floor)

1730 – 1930 CACMID Board Meeting (Youville – 3rd floor)

Wednesday April 60800 – 1200 CCM Workshop: Breakpoint – Counterpoint.

Defining a Canadian Perspective(Ville Mare – 9th floor)

0800 – 0830 Breakfast0800 – 1700 AMMI Canada Council Meeting

(St Sulpice – 3rd floor)

0800 – 0830 Breakfast1200 – 1745 TRAINEES’ DAY

(Ville Marie – 9th floor)

1200 – 1230 Lunch1230-1240 Welcome Lynn Johnston (Halifax, NS)1240-1250 What can AMMI Canada do for you? Vikas Chaubey (Calgary, AB)

Objectives:• Explain what AMMI Canada does for physicians;• Explain how residents can get involved;• Explain the benefits of AMMI Canada involvement.1250-1410 Diagnostic Research Madhukar Pai (Montreal, QC)

Objectives:• To demonstrate with examples from TB,

that test accuracy studies are often poorly conducted and reported

• To review the landscape of diagnostic research, using TB as an example, and highlight the need for studies that go beyond test accuracy

• To give examples of study designs that focus on outcomes such as incremental value of new tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness, and impact on patient-important outcomes

1410-1430 BREAK1430-1535 Community Practice vs

Academic PracticeAlicia Sarabia (Toronto, ON)

Objectives:• Outline advantages of community practice;• Identify challenges of community practice;• Present my personal experience.James Allan – (Montreal, QC)

Objectives:• Advantages of Community Practice• Challenges of Community Practice• My personal Experience

Educational Program


17

1030 – 1400 Poster viewing(McGill, Palais, Viger, Ramezay and St. Paul – 8th floor)

1030 – 1400 Student Poster viewing & judging(McGill and Palais – 8th floor)

1030 – 1400 Clinical Vignette Poster Viewing (McGill – 8th floor)

1100 – 1200 World Health Day News Conference(St Antoine B – 9th floor)

1130 – 1400 Royal College Specialty Committee in Medical Microbiology Meeting and Lunch(St Sulpice – 3rd floor)

Thursday April 70645 – 0800 AMMI Canada AGM/Sections Meetings

(Ville Marie A – 9th floor)

0645 – 0700 Breakfast0800 – 1030 PLENARY – EMERGING PROBLEMS IN

MULTI-DRUG RESISTANCE(Montréal Ballroom – 11th floor)Moderators: David Patrick and Suzanne Dale0800 – 0815 Welcome Remarks

and Introductions0815 – 0900 Gram Positives: Focus on MRSA

from bench to bedside Andy Simor (Toronto, ON)

Objectives: • To appreciate the changing epidemiology

of antibiotic-resistant Gram-positive microorganisms in Canadian hospitals.

• To consider newer diagnostic modalities for improved detection of antibiotic resistance in Gram-positive microorganisms.

• To review evidence-based recommendations for the management and prevention of infections caused by MRSA.

0900 – 0945 Gram Negatives: Mechanisms of resistance and laboratory detection Johann Pitout (Calgary, AB)

Objectives:• To understand the clinical significance

of bacteria that produce ESBLs, AmpC ß-lactamases and carbapenemases.

• To describe the molecular epidemiology of community-onset and nosocomial infections caused by bacteria that produce ESBLs, AmpC ß-lactamases and carbapenemases.

• To describe the laboratory detection of bacteria that produce ESBLs, AmpC ß-lactamases and carbapenemases.

0945 – 1030 Gram Negatives: Clinical management of the multi-drug resistant infections Karl Weiss (Montréal, QC)

Objectives:• To understand the clinical consequences

of infection with resistant Gram-negative microorganisms.

• To discuss the available therapeutic options for emerging Gram-negative microorganisms.

1030 – 1400 Exhibit Hall Open / Break and Delegate Lunch Exhibit Hall (8th floor)

Educational Program

1200 – 1400 Pfizer (Infectious Diseases) Integrated Symposiumco-developed with AMMI Canada(Fortifications Ballroom - 9th floor)

Lunch will be served A New Look at MRSA Pneumonia: Epidemiology,

2011 Guidelines and Recent Trials Moderator: Linda Dresser (Toronto, ON) Speakers: Ethan Rubinstein (Winnipeg, MB) Daniel Thirion (Montréal, QC) Objectives:

• To identify the epidemiology and clinical features of MRSA nosocomial pneumonia and CA-MRSA community acquired MRSA pneumonia.

• To describe the therapeutic endpoints and treatment options.

• To discuss data on recent clinical trials.

1200 – 1400 AMMI Canada – Guidelines Committee Meeting(Youville – 3rd floor)

1400 Exhibit Hall Closes 1400 – 1500 Exhibitor Debrief (Diagnostic)

(Le Moyne – 8th floor)

1415 – 1515 State of the Art Clinical Lecture (Montréal Ballroom – 11th floor)

Moderator: Susan Poutanen C. difficile infection (CDI) –

what’s new, what’s old and what’s different? Mark Miller (Montréal, QC)

Objectives:• To provide an update on the global

epidemiology of CDI.• To describe the methodology for classifying

CDI patients by severity of disease.• To provide an update on the current

and soon-to-be-available therapies for CDI.• To provide an overview of diagnostics

and infection control for CDI.1515 – 1530 Break (Montréal Ballroom Foyer)


18

A5 1630 -1645 Impact of CA-MRSA on Population-Based

Antimicrobial Use for Skin and Soft Tissue InfectionsF MARRA1,2, D PATRICK1,2, M CHONG2, R MCKAY2, W BOWIE1

1University of British Columbia, Vancouver, BC; 2BC Centre for Disease Control, Vancouver, BC

A6 1645 – 1700 Community and Hospital Antibiotic Profiles of Group

B Streptococcus for Penicillin, Erythromycin and Clindamycin in Vancouver CanadaT WONG1, S DHALIWAL2, G AL-RAWAHI1, C PIENAAR1,3, M KELLY1,3, L MARTINEZ3, R REYES1,3

1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 2Division of Medical Microbiology, The Department of Pathology and Laboratory Medicine, BC Children’s Hospital and Women’s Health Centre; Vancouver, BC; 3LifeLabs Medical Laboratory Services, Vancouver, BC

1530 – 1715 Oral Presentations Session B Room: St. Antoine A (9th floor)

Moderator: Tim KarnauchowB1 1530 - 1545 Performance and Workflow Comparison of

Cervista® HPV HR and HC2 on SurePath Liquid-based Pap SpecimensJ KAPALA1, N HARROUN1, D JANG2, K BIERS1, J GILCHRIST2, R TOOR2, J SUMNER1, M CHERNESKY2

1Gamma Dynacare Medical Laboratories, Brampton, ON; 2McMaster University/St. Joseph’s Healthcare, Hamilton, ON

B2 1545 - 1600 Comparison of the Roche cobas® 4800 vs. Qiagen

hc2® Tests for Detection of High-Risk HPV DNAK CEBALLOS1,2, D VAN NIEKERK1,2, W MEI3, D COOK3, R SHOW3, L SMITH2, E FRANCO4, G OGILVIE1,3, A COLDMAN1,2, M KRAJDEN1,3

1University of British Columbia, Vancouver, BC; 2BC Cancer Agency, Vancouver BC; 3BC Centre for Disease Control, Vancouver, BC; 4McGill University, Montreal, QC

B3 1600 -1615 Modified Triplex Quantitative PCR Assay for

Human Polyomaviruses JC and BKV GOLESKI, T DUMONCEAUX, A SEVERININational Microbiology Laboratory, Winnipeg, MB

1530 – 1700 Oral Presentations Session A Room: Ville Marie A (9th floor)

Moderator: Lynora SaxingerA1 1530-1545 A Professional and Public Awareness Campaign

to Promote the Prudent Use of Antibiotics: Antibiotic Awareness Day Canada 2010K BUNZELUK1, L SAXINGER2, K LARYEA3, G LOVAGI4, G HANSEN5, R BARCLAY1, T DONALDSON3, M FAST1, A FAGAN3, E HYDESMITH1

1National Collaborating Centre for Infectious Diseases, Winnipeg, MB; 2AMMI Canada Stewardship and Resistance Committee/University of Alberta, Edmonton, AB; 3Public Health Agency of Canada, Ottawa, ON; 4Association of Medical Microbiology and Infectious Disease (AMMI) Canada, Ottawa, ON; 5Community and Hospital Infection Control Association, Winnipeg, MB

A2 1545 - 1600 Changes in Antibiotic Utilization for

Acute Otitis Media among ChildrenF MARRA1,2, D PATRICK1,2, M CHONG2, R MCKAY2, E BLONDEL-HILL3, K DREHER2, W BOWIE1

1University of British Columbia, Vancouver, BC; 2BC Centre for Disease Control, Vancouver, BC; 3Interior Health Authority, Vancouver, BC

A3 1600 - 1615 Antibiotic Utilization for Upper Respiratory

Infection: Revelations from Time Series Analysis in the Era of the Do Bugs Need Drugs? (DBND) ProgramD PATRICK1,2, F MARRA1,2, M CHONG2, R MCKAY2, K DREHER2, W BOWIE1, E BLONDEL-HILL1,3

1University of British Columbia, Vancouver, BC; 2British Columbia Centre for Disease Control, Vancouver, BC; 3Interior Health Authority, Kelowna, BC

A4 1615-1630 Methicillin-Resistant Staphylococcus aureus

(MRSA) Bloodstream Infections (BSIs) in Canadian Hospitals from 1995 to 2009A MOUNCHILI1, A SIMOR1,2, D GRAVEL1, M MULVEY2, E BRYCE4, A MATLOW6, M LOEB5, A MCGEER7, Canadian Nosocomial Infection Surveillance Program1

1Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa; 2Sunnybrook Health Sciences Centre, Toronto, ON; 3National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 4Vancouver General Hospital, Vancouver, BC; 5The Hospital for Sick Children, Toronto; 6Hamilton Health Sciences Corporation, Hamilton; 7Mount Sinai Hospital, Toronto, ON

Educational Program


19

C2 1545 - 1600 Practical Bench Comparison of 3 Chromogenic

and 2 Standard Urine Culture Media for Detection and Identification of Urinary Tract PathogensP KORNHERR1, D DOWHANIUK1, C GHOSH2, M GUZMAN2, L LEWIS2, R PIZARRO1, J KAPALA2

1Gamma-Dynacare Medical Laboratories, Ottawa, ON; 2Gamma-Dynacare Medical Laboratories, Toronto, ON

C3 1600 1615 Determining Penicillin (Pen) and Ceftriaxone

(Cro) MIC in Streptococcus pneumoniae (SPN): Evaluation of Commercially Available Trek Sensititre Broth Microdilution (BMD) and bioMerieux’s Etest Gradient Strips using Two Brands of Mueller-Hinton Blood Agar (MHBA)BM WILLEY1, K PRAYITNO2, T FUNG2, A YEBOAH1, C LAROCQUE1, H NG1, K SCHOER1, N BERESFORD1, P LO1, S PONG-PORTER1, AJ MCGEER1,2, SM POUTANEN1,2

1Mount Sinai Hospital/University Health Network, Toronto, ON; 2University of Toronto, Toronto, ON

C4 1615 - 1630 Comparison of chromogenic culture methods for

detection of Vancomycin Resistant Enterococci (VRE)W JANG, G RITCHIE, M ROMNEY, S CHAMPAGNE, A WONG, J TARUC, J BILAWKAProvidence Health Care, Vancouver, BC

C5 1630 - 1645 Evaluation of the Inverness Colorex (CX) and

Oxoid Brilliant Blue (BB) Chromogenic Agar for the Detection and Differentiation of Vancomycin (Van) Resistant Enterococcus (VRE)M DESJARDINS1,2, K JESSAMINE2, T LEWIS2

1The Ottawa Hospital, Ottawa, ON; 2The Ottawa Hospital Research Institute, Ottawa, ON

C6 1645 - 1700 Evaluation of the Vitek™ AST-GP67 Card for

detection of MRSA – Results from >1300 clinical Staphylococcus aureus isolatesP LAGACÉ-WIENS1,2, M ALFA1,2, K MANICKAM1,2

1Diagnostic Services of Manitoba, Winnipeg, MB; 2University of Manitoba, Department of Medical Microbiology and Infectious Diseases, Winnipeg, MB

B4 1615 - 1630 Development and Evaluation of a Real Time

RT-PCR Assay for Specific Detection of Enteroviruses on a Variety of Specimen TypesS WONG1, K PABBARAJU1, KL GILL1, R TELLIER1,2

1Provincial Laboratory For Public Health (Microbiology), Calgary, AB; 2Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB

B5 1630 - 1645 Comparison of Western Blot and Inno-LIA for

Serological Human Immunodeficiency Virus (HIV) DiagnosisK KADIVAR, J KIMPublic Health Agency of Canada, Ottawa, ON

B6 1645 - 1700 External Quality Assessment (EQA) of Influenza (Flu)

and Respiratory Syncytial (RSV) Viruses Using Simulated Specimens for Direct Detection MethodsM COUILLARD1, R LAMIRANDE1, P TURCOTTE1, H CHAREST1, C BÉLIVEAU2, A-M BOURGAULT1

1Laboratoire de santé publique, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC; 2Hôpital Maisonneuve-Rosemont, Montréal, QC

B7 1700 - 1715 Pilot Study of Dengue in Tegucigalpa, Honduras

J SRIGLEY1, K HAMILTON1, S ESKANDARIAN1, L CHILDERHOSE1, E FERNANDEZ2, I LORENZANA3, M LOEB1,2,4,5

1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON; 3National Microbiology Laboratory, Tegucigalpa, Honduras, 4Department of Medicine, McMaster University, Hamilton, ON; 5Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON

1530 – 1700 Oral Presentations Session C Room: Ville Marie B (9th floor)

Moderator: Gregory TyrrellC1 1530 -1545 Performance Comparison of Ontario versus U.S.

Laboratories on Enteric Parasitology External Quality Assessment (EQA)/Proficiency Testing (PT) SurveysCA FLEMING, A SARABIA, M DESJARDINS, F JAMIESON, K KATZ, H MEANEY, SM POUTANEN, D RAYMONDO, J GUN-MUNRO, G FLYNNQuality Management Program - Laboratory Services, Toronto, ON

Educational Program


20

D3 1600 - 1615 Household Transmission of Community- and

Healthcare-associated Methicillin Resistant Staphylococcus aureus StrainsK KATZ1,2, P GNANASUNTHARAM3, A FAHEEM1, A GELOSIA3, L LOUIE4, A MCGEER2,3, M MULLER2,5, W NG1, K OSTROWSKA6, D RICHARDSON7, L VERNICH2, H WONG4, A SIMOR2,4

1North York General Hospital; 2University of Toronto; 3Mount Sinai Hospital; 4Sunnybrook Health Sciences Centre; 5St Michael’s Hospital; 6Trillium Health Centre, Toronto; 7William Osler Health System, Brampton, ON

D4 1615 - 1630 Gastro-Intestinal Outbreaks in Long Term Care

Facilities, Hospital and Day Care Centres in British ColumbiaN PRYSTAJECKY1,2, B AUK1, J WONG1, J FUNG1, B WONG1, P TANG1,2, J ISAAC-RENTON1,2

1British Columbia Centre for Disease Control Public Health and Reference Laboratory (BCPHL), Vancouver, BC; 2University of British Columbia - Department of Pathology and Laboratory Medicine, Vancouver, BC

D5 1630 - 1645 A Shelter Associated Tuberculosis Outbreak:

Lessons ForgottenD MOREAU1, R AHMED1,2, E DER1, D KUNIMOTO1,2, L CHUI3,4

1Edmonton TB Clinic, Edmonton, AB; 2Department of Medicine, University of Alberta, Edmonton, AB; 3Provincial Laboratory for Public Health, Edmonton, AB; 4Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB

D6 1645 - 1700 A Mathematical Model of Nosocomial Clostridium

Difficile Infection (CDI) Transmission in an Acute Care Hospital System with Seasonal Variations in Transmission RateK BROWN, D FISMANDalla Lana School of Public Health, Toronto, ON

1700 – 1900 Welcome Reception (Exhibit Hall – 8th floor)

1530 – 1700 Oral Presentations Session D Room: St. Antoine B (9th floor)

Moderator: Gerald EvansD1 1530 1545 Characterization of Carbapenem-Resistant

Acinetobacter baumanii and Pseudomonas spp. in CanadaLF MATASEJE1, D BOYD1, E BRYCE2, D ROSCOE2, J EMBREE3, D GRAVEL4, P KIBSEY5, A MOUNCHILI4, A SIMOR6, M KUHN7, N TURGEON8, E THOMAS9, G TAYLOR10, MR MULVEY1

1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 2Vancouver General Hospital, Vancouver, BC; 3University of Manitoba, Pediatric Infectious Diseases, Winnipeg, MB; 4Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 5Victoria General Hospital, Victoria, BC; 6Sunnybrook Health Science Centre, Toronto, ON; 7The Moncton Hospital, Moncton, NB; 8Hotel-Dieu de Quebec du CHUQ, Quebec City, QC; 9Children’s and Women’s Health Centre, Vancouver, BC; 10University of Alberta, Edmonton, AB

D2 1545 - 1600 Prevalence of Broad Spectrum Beta Lactamase

Producing Enterobacteriaceae in Stool Samples Submitted to Okanagan Region Hospitals in British ColumbiaM HOOPER1, V HADWELL2, E BLONDEL-HILL2,3

1University of Victoria, Victoria, BC; 2Kelowna General Hospital, Kelowna; 3University of British Columbia, Vancouver, BC

Educational Program


21

1030 – 1130 CCM - AGM (Ville Marie B – 9th floor)

1030 – 1400 Exhibit Hall Open / Break (sponsored by Alere) and Delegate LunchExhibit Hall (8th floor)

1030 – 1400 Poster Viewing(McGill, Palais, Viger, Ramezay and St. Paul – 8th floor)

1030 – 1400 Student Poster viewing(McGill and Palais – 8th floor)

1030 – 1400 Clinical Vignette Poster Viewing (McGill – 8th floor)

1130 – 1400 Royal College Specialty Committee in Infectious Diseases Meeting and Lunch(St Sulpice – 3rd floor)

1130 – 1400 AMMI Canada – Antimicrobial Stewardship and Resistance Committee Meeting (Notre Dame – 3rd floor)

1200 – 1400 National Microbiology Diagnostics User Group Meeting(Ville Marie B – 9th floor)

Friday April 80645 – 0800 CACMID AGM

(Ville Mare B – 9th floor)

0645 – 0700 Breakfast0800 – 1030 PLENARY – HIV UPDATE

(Montréal Ballroom – 11th floor) Moderators: Matthew Oughton and

Jonathan Gubbay0800 – 0815 Welcome Remarks

and Introductions0815 – 0900 The Pathobiology of HIV

Cécile Tremblay (Montréal, QC) Objectives:

• To review the early events occurring during primary HIV infection

• To understand the obstacles to viral eradicaton • To understand the role of chronic immune

activation on HIV pathogenesis

0900 – 0945 Current challenges in the management of HIV Infections Sharon Walmsley (Toronto, ON)

Objectives:• To gain a better understanding of the

improvements in HIV morbidity and mortality with time.

• To better appreciate that, despite advances with ARV, therapy challenges remain, especially with respect to short and long term adverse drug effects.

• To understand the new challenges of comorbidities that face HIV infected individuals as they age.

• To appreciate the potential for drug interactions between ARV and other therapies that HIV patients may require.

0945 – 1030 A global view of the HIV pandemicRéjean Thomas (Montréal, QC)

Objectives:• To understand components of the HIV epidemic.• To update new HIV treatments.• Patient management update: When to start

HIV treatment.

Educational Program

1200 – 1400 Novartis Integrated Symposium co-developed with AMMI Canada

(Fortifications Ballroom - 9th floor) Lunch will be served A Universal Meningococcal B Vaccine: A Novel

Genomic Approach to Vaccine Development and Evaluation

Moderator: Brian Ward (Montreal, QC) Speakers: Richard Moxon (Oxford, UK) Duccio Medini (Milan, Italy) Objectives:• Describe the epidemiology of

meningococcal disease. • Recognize reverse vaccinology as applied

to the development of a broadly protective 4CMenB vaccine.

• Discuss the Phase II and Phase III clinical data describing the immunogenicity and safety of a 4CMenB vaccine from infants and adults.

• Review the application of a new antigen typing assay in the evaluation of potential effectiveness against diverse MenB strains.

1400 Exhibit Hall Closes 1400 – 1500 Exhibitor Debrief (Pharma)

(Le Moyne – 8th floor)


22

E3 1600 - 1615 Characterization of Carbapenem-Resistant

Enterobacteriaceae in Canada: Results of the Canadian Nosocomial Surveillance Program (CNISP)LF MATASEJE1, D BOYD1, E BRYCE2, D ROSCOE2, J EMBREE3, D GRAVEL4, P KIBSEY5, A MOUNCHILI4, A SIMOR6, M KUHN7, N TURGEON8, E THOMAS9, G TAYLOR10, MR MULVEY1

1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 2Vancouver General Hospital, Vancouver, BC; 3University of Manitoba, Pediatric Infectious Diseases, Winnipeg, MB; 4Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 5Victoria General Hospital, Victoria, BC; 6Sunnybrook Health Science Centre, Toronto, ON; 7The Moncton Hospital, Moncton, NB; 8Hotel-Dieu de Quebec du CHUQ, Quebec City, QC; 9Children’s and Women’s Health Centre, Vancouver, BC; 10University of Alberta, Edmonton, AB

E4 1615 - 1630 Canada’s First Case of a Multi-Drug Resistant

Corynebacterium diphtheriae, Isolated From a Skin AbscessN MINA1, K BERNARD2,3, T BURDZ2, D WIEBE2, JS RAI4, L HOANG5,6

1University of Alberta, Department of Medical Microbiology, Edmonton, AB; 2National Microbiology Laboratory, Public Health Agency of Canada; 3University of Manitoba, Department of Medical Microbiology, Winnipeg, MB; 4Family Physician, Delta; 5BCCDC Public Health Reference Microbiology Laboratory, Provincial Health Services Authority; 6University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, BC

E5 1630 - 1645 Daptomycin for High Grade Gram Positive

Infections: A Canadian Tertiary Hospital ExperienceS HAIDER, A BROOKSMcMaster University, Hamilton Health Sciences, Hamilton, ON

E6 1645 - 1700 Symptom-reporting Compared with Audiometry

for the Detection of Ototoxicity in Patients on Long-term Aminoglycoside TherapyL PALMAY1, SAN WALKER1,2, SE WALKER1,2, A SIMOR1,2

1Sunnybrook Health Sciences Centre, Toronto, ON; 2University of Toronto, Toronto, ON


Moderator: Todd Hatchette Emerging viral pathogens

Michael Drebot (Winnipeg, MB) Objectives:

• Attendees will learn that the majority of emerging viral pathogens are zoonotic or of animal origin.

• Attendees will learn that vector-borne viruses make up a significant portion of emerging infectious disease world wide.

• Attendees will learn about new Canadian research initiatives involving novel and neglected mosquito-borne pathogens.

• Attendees will learn about recent innovations in diagnostic platforms and testing algorithms for identifying emerging zoonotic agents.

1515 – 1530 Break (9th floor foyer)

1530 – 1700 Oral Presentations Session E Room: Ville Marie A (9th floor)

Moderator: Linda HoangE1 1530 - 1545 Antimicrobial Resistance in Pathogens Isolated

from Canadian Hospital Clinics, Emergency Rooms, Medical/Surgical Wards and Intensive Care Units: Results of the CANWARD 2010 StudyM DeCORBY1, HJ ADAM1,2, L MATASEJE3, MR MULVEY1,3, JA KARLOWSKY1,2, P LAGACE-WIENS1,2, A WALKTY1,2, DJ HOBAN1,2, GG ZHANEL1

1University of Manitoba, Winnipeg, MB; 2Diagnostic Services of Manitoba, Winnipeg, MB; 3National Microbiology Laboratory, Winnipeg, MB

E2 1545 - 1600 Vancomycin-Resistant Enterococci (VRE) -

Findings from the Canadian Nosocomial Infection Surveillance Program (CNISP), 2006-2009R MITCHELL1, J EMBIL2, J CONLY3, D GRAVEL1, L JOHNSTON4, S LEDUC1, A MATLOW5, M MULVEY1,6, D ORMISTON2, A SIMOR7, A WONG8, D ZOUTMAN9, Canadian Nosocomial Infection Surveillance Program1

1Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 2Health Sciences Centre, Winnipeg, MB; 3Foothills Medical Centre, Calgary, AB; 4Queen Elizabeth II Health Sciences Centre, Halifax, NS; 5Hospital for Sick Children, Toronto, ON; 6Sunnybrook Health Sciences Centre, Toronto, ON; 7Royal University Hospital, Saskatoon, SK; 8Kingston General Hospital, Kingston, ON; 9National Microbiology Laboratory, Winnipeg, MB

Educational Program


23

1530 – 1700 Oral Presentations Session G Room: Ville Marie B (9th floor)

Moderator: Lynn JohnstonG1 1530 - 1545 Detection of Varicella-Zoster Virus (VZV) from

Genital SpecimensA MAK1, M PETRIC1,2, M KRAJDEN1,2, P TANG1,2

1PHSA Laboratory, BCCDC, Vancouver, BC; 2University of British Columbia, Vancouver, BC

G2 1545 - 1600 Investigation of a Human Rhinovirus Outbreak in

a Canadian Long-Term Care FacilityS MUBAREKA1,2, L LOUIE1, O YOW1, A GRANADOS3,4, K LUINSTRA3, H WONG1, A ARORA1, S CHONG3, A PETRICH5, M VEARNCOMBE1,2, A SIMOR1,2, J MAHONY3,4, M SMIEJA3,4

1Sunnybrook Health Sciences Centre and Research Institute, Toronto, ON; 2University of Toronto, Toronto, ON; 3St. Joseph’s Hospital, Hamilton, ON; 4McMaster University, Hamilton, ON; 5The Hospital for Sick Children, Toronto, ON

G3 1600 -1615 Comprehensive Microbiological Analysis of Fatal

Cases of Pandemic Influenza A Virus (H1N1)S PATEL1,2, A MARCHAND-AUSTIN1,3, J LONGTIN1, E LOMBOS1, P TANG1, P RAWTE1, D LOW1,2,4, J GUBBAY1,2,4, F JAMIESON1

1Ontario Agency for Health Protection and Promotion, Toronto, ON; 2University of Toronto, Toronto, ON; 3Public Health Agency of Canada, Winnipeg, MB; 4Mount Sinai Hospital, Toronto, ON

G4 1615 - 1630 Why Did Health Care Workers refuse the pH1N1

Vaccine during the Pandemic?K CORACE1, C PREMATUNGA1, A MCCARTHY1, V ROTH1, T HAYES2, KN SUH1, L BALFOUR1, G GARBER1

1The University of Ottawa at The Ottawa Hospital, Ottawa, ON; 2The Ottawa Hospital, Ottawa, ON

G5 1630 - 1645 Self-reported Influenza Vaccination, Illness and

Absenteeism among Canadian Healthcare Workers during the 2009 H1N1 Influenza PandemicR MITCHELL1, G ASTRAKIANAKIS2, E BRYCE3, R GERVAIS1, D GRAVEL1, L JOHNSTON4, S LEDUC1, V ROTH5, G TAYLOR6, M VEARNCOMBE7, K WILKINSON1, Canadian Nosocomial Infection Surveillance Program1

1Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 2University of British Columbia, Vancouver, BC; 3Vancouver General Hospital, Vancouver, BC; 4Queen Elizabeth II Health Sciences Centre, Halifax, NS; 5The Ottawa Hospital, Ottawa, ON; 6University of Alberta Hospital, Edmonton, AB; 7Sunnybrook Health Sciences Centre, Toronto, ON

1530 – 1700 Oral Presentations Session F Room: St. Antoine A (9th floor)

Moderator: Karam RamotarF1 1530 - 1545 Selection of DNA aptamers specific for

Group A Streptococcal M typesC HAMULA, X LI, C LEUniversity of Alberta, Edmonton, AB

F2 1545 - 1600 Cost-effective modification of the BD GeneOhm™

C difficile assayL LOUIE1, A SIMOR1,2

1Sunnybrook Health Sciences Centre, Toronto, ON; 2University of Toronto, Toronto, ON

F3 1600 - 1615 Detection of Enteric Pathogens in Community

and Hospital Diarrhea Cases using a Multiplex PCR AssayL CHUI1,2, J FUNG1, M-C LEE3, K MALEJCZYK2

1Provincial Laboratory for Public Health, Edmonton, AB; 2Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; 3DynaLIFE DX Laboratory Services, Edmonton, AB

F4 1615 - 1630 Confirmation of the Roche COBAS AMPLICOR 480

Neisseria gonorrhea molecular assay with an in-house real-time polymerase chain reaction assayS DREWS1,2, L CHUI1,3,4, L DOUGLAS1,4, G ZAHARIADIS1,3,4, G TYRRELL1,3,4

1ProvLab Alberta, AB; 2Microbiology and Immunology, University of Calgary, Calgary, AB; 3Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; 4University of Alberta Hospital, Edmonton, AB

F5 1630 - 1645 Taq Probing: A New Molecular Diagnostic Method

Applied to Detect SNP Associated with Antibiotic Resistance in Campylobacter jejuniP DEXTRAS PAQUETTE1, S DESLANDES1, EH FROST1,2

1Université de Sherbrooke, Sherbrooke, QC; 2Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC

F6 1645 - 1700 Development of Molecular Biology and

Bioinformatics Tools for the Identification of Fungal Pathogens in a Reference Laboratory SettingH CHAREST, R CANTIN, G ST-GERMAINLaboratoire de santé publique du Québec/INSPQ, Sainte-Anne-de-Bellevue, QC

Educational Program


24

H4 1615 - 1630 Multi-locus Sequence Typing of Coastal Pacific

Northwest Cryptococcus IsolatesM-K LEE, S MAN, A BALBIRNIE, S MITHANI, Q WONG, L HOANG, MG MORSHEDBritish Columbia Centre for Disease Control Public Health and Reference Laboratory (BCPHL), Vancouver, BC

H5 1630 - 1645 Preliminary Evidence of Cache Valley Virus

Infections and Associated Human Illness in Western Canada in 2009K DIMITROVA1, M ANDONOVA1, K MAKOWSKI1, K HOLLOWAY1, PN LEVETT3, K KADKHODA2, P VAN CAESEELE2, MA DREBOT11Public Health Agency of Canada, Winnipeg, MB; 2Cadham Provincial Laboratory, Winnipeg, MB; 3Saskatchewan Disease Control Laboratory, Regina, SK

H6 1645 - 1700 The Identification of Probable Cases of California

Serogroup Virus Infections in Manitoba in 2010K MAKOWSKI1, K DIMITROVA1, M ANDONOVA1, K HOLLOWAY1, K KADKHODA2, P VAN CAESEELE2, MA DREBOT11Public Health Agency of Canada, Winnipeg, MB; 2Cadham Provincial Laboratory, Winnipeg, MB

G6 1645 – 1700 Reported Use of Personal Protective Equipment

(PPE) among Canadian Healthcare Workers (HCWs) During the Second Wave of the H1N1 Influenza PandemicR MITCHELL1, G ASTRAKIANAKIS2, E BRYCE3, R GERVAIS1, D GRAVEL1, L JOHNSTON4, S LEDUC1, V ROTH5, G TAYLOR6, M VEARNCOMBE7, C WEIR1, Canadian Nosocomial Infection Surveillance Program1

1Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 2University of British Columbia, Vancouver, BC; 3Vancouver General Hospital, Vancouver, BC; 4Queen Elizabeth II Health Sciences Centre, Halifax, NS; 5The Ottawa Hospital, Ottawa, ON; 6University of Alberta Hospital, Edmonton, AB; 7Sunnybrook Health Sciences Centre, Toronto, ON

1530 – 1700 Oral Presentations Session H Room: St. Antoine B (9th floor)

Moderator: Kathy BernardH1 1530 - 1545 Extensive Genomic Variation within Clonal

Complexes of Neisseria meningitidisW HAO1,2, J MA1, K WARREN1, P TSANG3, D LOW1,2, F JAMIESON1,2, D ALEXANDER1,2

1Ontario Agency for Health Protection and Promotion, Public Health Laboratories, Toronto, ON; 2University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON; 3Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, MB

H2 1545 - 1600 Whole Genome Analyses and Epidemiological

Aspects of a Proposed New Epidemic Clone of Listeria monocytogenes in CanadaA REIMER1, M WALKER1, S TYLER1, J ZIEGLER1,2, C SINGH1, P HEMMONS1,3, C CROSS1, M GRAHAM1, G VAN DOMSELAAR1, V ALLEN4, F PAGOTTO5, M GILMOUR1,2

1Public Health Agency of Canada, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB; 3Thompson Rivers University, Kamloops, BC; 4Ontario Agency for Health Protection and Promotion, Toronto, ON; 5Health Canada, Ottawa, ON

H3 1600 - 1615 Provisional Taxon,CDC group NO-1, represents

a new genus in the family Comamonadaceae, linked to zoonotic-based wounds / other infections in humansK BERNARD1,2, T BURDZ1, B NG1, AL PACHECO1, D WIEBE1, A REIMER1

1National Microbiology Laboratory PHAC, Winnipeg, MB; 2University of Manitoba Department of Medical Microbiology, Winnipeg, MB

Educational Program

1715 - 1915 Pfizer (Vaccines) Integrated Symposium co-developed with AMMI Canada

(Fortifications Ballroom - 9th floor) Dinner will be served Adult Pneumococcal Disease in Canada:

Current trends and Future Considerations Speakers: Louis Valiquette (Sherbrooke, QC) Karl Weiss (Montréal, QC) Brian Ward (Montréal, QC) Objectives:

• Understand the impact of childhood pneumococcal vaccinations on the adult population; and the prevalence of pneumococcal pneumonia (including serotype distribution) in the adult community, based on Canadian surveillance data.

• Examine the clinical implications of S. pneumoniae in Canada, in terms of consequences of treatment (i.e., resistance, C. difficile), and the potential need for new prevention measures.

• Compare the immune responses to conjugated vs non-conjugated vaccines.

• Discuss the advantages and disadvantages of polysaccharide versus pneumococcal con-jugate vaccines at different ages.


25

1045 - 1145 Oral Presentations Session IRoom: Ville Marie A (9th floor)

Moderator: Mark JoffeI1 1045 - 1100 Chronic Hepatitis E in a Canadian

HIV infected patientA ANDONOV1, M POLIQUIN2, L LIN1, A MASON3, D MURPHY2,4

1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 2CHUM-Clinique Medicale L’Actuel, Montreal, QC; 3University of Alberta, Edmonton, AB; 4Laboratoire de sante publique du Quebec, Montreal, QC

I2 1100 - 1115 Successful Cardiac Transplantation in a 4-year

old Child with Active Parainfluenza-3 Infection: Experience with Systemic Ribavirin TherapyJ KANJI, W VAUDRYUniversity of Alberta, Edmonton, AB

I3 1115 - 1130 Laboratory-Confirmed Pandemic H1N1 Influenza

in Hospitalized Adults - Findings from the Canadian Nosocomial Infection Surveillance Program (CNISP), 2009-10K WILKINSON1, G TAYLOR2, D GRAVEL1, B AMIHOD3, C FRENETTE4, AJ MCGEER5, D MOORE6, KN SUH7, A WONG8, R MITCHELL1

1Public Health Agency of Canada, Ottawa, ON; 2University of Alberta Hospital, Edmonton, AB; 3The Jewish General Hospital, Montreal, QC; 4McGill University Health Centre, Montreal QC; 5Mt. Sinai Hospital, Toronto, ON; 6Montreal Children’s Hospital, Montreal, QC; 7The Ottawa Hospital, Ottawa, ON; 8Royal University Hospital, Saskatoon, SK

I4 1130 - 1145 Epidemiological Features and Pathogens

Associated with Meningitis among Children [0-15 Years]S THLIZA1, T LAWOYIN2, I JALO3

1Hospitals Management Board Headquarters, Maiduguri, Borno State, Nigeria, 2Reproductive and Family Health Unit, Department of Community Medicine, College of Medicine, UCH, Ibadan, Oyo State, Nigeria, 3Department of Paediatrics, Federal Medical Centre, Gombe, Gombe State, Nigeria

Saturday April 9 0800 – 1030 PLENARY – REVIEW OF CLINICAL MICROBIOLOGY

AND INFECTIOUS DISEASES: WHAT’S NEW AND WHAT’S HOT?(Montréal Ballroom – 11th floor)

Moderators: Matthew Gilmour and Linda Hoang0800 – 0815 Welcome Remarks

and Introductions0815 – 0900 What’s Hot in Adult

Infectious Disease? Mark Joffe (Edmonton, AB)

Objectives:• To highlight a selection of the most important

and interesting literature in clinical infectious diseases from the last year.

• To astonish, astound and amuse with the extent and breadth of clinical and basic research in our field.

0900 – 0945 What’s Hot in Paediatric Infectious Disease? Dorothy Moore (Montréal, QC)

Objectives: • To highlight recent developments in the

prevention, diagnosis and treatment of selected infectious diseases of children.

• To consider how these developments may influence clinical practice.

0945 – 1030 New Developments in Molecular Microbiology Diagnostics Astrid Petrich (Toronto, ON)

Objectives:• To provide an overview of the current state

of molecular microbiology diagnostics in Canadian laboratories.

• To review some of the factors involved with laboratories offering new molecular assays in microbiology.

• To discuss some of the new developments in technology and instrumentation in molecular microbiology diagnostics.

1030 – 1045 Break (Montréal Ballroom Foyer)

Educational Program


26

1045 - 1145 Oral Presentations Session KRoom: Ville Marie B (9th floor)

Moderator: Kevin ForwardK1 1045 - 1100 Post-arrival Screening for Malaria in

Asymptomatic Refugees Using Real-time PCRC MATISZ1, P NAIDU2, S SHOKOPLES1, D GRICE3, V KRINKE3, SZ BROWN4, K KOWALEWSKA-GROCHOWSKA2, S HOUSTON2, SK YANOW1,2

1Provincial Laboratory for Public Health, Edmonton, AB; 2University of Alberta, Edmonton, AB; 3New Canadians Clinic, Edmonton, AB; 4DynaLife Diagnostic Laboratory Services, Edmonton, AB

K2 1100 – 1115 Chagas Donor Screening at Canadian

Blood ServicesM FEARON1,2, V SCALIA3, I DINES1, M HUANG1, M NDAO4,5

1Canadian Blood Services, Toronto,ON; 2Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON; 3Canadian Blood Services, Ottawa, ON; 4National Reference Centre for Parasitology, Montreal, QC; 5McGill University Centre for Tropical Diseases, Montreal, QC

K3 1115 - 1130 Genotyping of Twenty Years of Pathogenic

Acanthamoeba Isolates from British Columbia: A Preliminary ReportM-K LEE, S MAN, T LO, Q WONG, JL ISAAC-RENTON, MG MORSHEDBritish Columbia Centre for Disease Control Public Health Microbiology and Reference Laboratory (BCPHL), Vancouver, BC

K4 1130 - 1145 Molecular Characterization of West Nile virus

strains in Western North AmericaM-K LEE1, S MAN1, K FERNANDO1, T LO1, Q WONG1, P TANG1, B HENRY2, V BOWES3, S DREWS4, R BAKER5, MG MORSHED1

1British Columbia Centre for Disease Control Public Health Microbiology and Reference Laboratory (BCPHL), Vancouver, BC; 2British Columbia Centre for Diseases Control Public Health Emergency Services, Vancouver, BC; 3Animal Health Centre, Abbotsford, BC, 4Provincial Laboratory for Public Health, Calgary, AB; 5Oregon State University, Corvallis, OR, United States

1045 - 1145 Oral Presentations Session JRoom: St. Antoine A (9th floor)

Moderator: Heather AdamJ1 1045 - 1100 Evaluation of WASP Automated Microbiology

Specimen Processor for the Processing of Urine Specimens in a High Volume LaboratoryN SHARMA1, H ALMOHRI1,2, S SMITH1, C BECHARD1, P ROMANO1

1LifeLabs Medical Laboratories, Toronto, ON; 2Joseph Brant Memorial Hospital, Burlington, ON

J2 1100 - 1115 Comparison between BD ViperTM XTR System and

GenProbe Tigris® DTS® System for the Detection of CT/GC in Urine Specimens and Genital SwabsH ALMOHRI1,2, S BOSS1, S SMITH1, D SEALY1, M KELLY3, G RITCHIE4, J BITTANTE3, M WONG3

1LifeLabs Medical Laboratory Services, Toronto, ON; 2Joseph Brant Memorial Hospital, Burlington; 3LifeLabs Medical Laboratory Services, Burnaby; 4Providence Health Care, Vancouver, BC

J3 1115 - 1130 Multi-site evaluation of two enzyme immunoassays

for verotoxins (shigatoxins) in clinical stool samplesL HOANG1,2, D CARRANZA3, M CASTRO1, J DALY4,5, B H OLTSLANDER3, S MALOTT4, A MAZZOCCO3, A PACCAGNELLA1, SE RICHARDSON6, T WONG1, R JOHNSON3

1BCCDC Public Health and Reference Microbiology Laboratory, PHSA; 2UBC Department of Pathology and Laboratory Medicine, Vancouver, BC; 3Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Guelph, ON; 4Microbiology Laboratories Primary Children’s Medical Center; 5Department of Pathology, University of Utah, Salt Lake City, UT, United States; 6Division of Microbiology, The Hospital for Sick Children, Toronto, ON

J4 1130 - 1145 A Prospective Comparative Study of Antigen

Detection (Galactomannan) versus Conventional Diagnosis of Invasive Aspergillosis and Impact on Patient OutcomeS JOHN1, M ALAWI1, B AHMED2, S HAIDER1, I WALKER1, D YAMAMURA1, C KIM2, C LEE1,2

1McMaster University, Hamilton, ON; 2St Joseph’s Healthcare, Hamilton, ON

Educational Program


27

• Describe and recognize the role of each class of antibiotics in the development of carbapenemases.

• Contrast treatment options for NDM-1 and KPC carbapenamases

• Define appropriate vs. inappropriate usage of carbapenem antibiotics.

• Review current and future stewardship as well as infectious disease control strategies for carbapenemases.

• Review the clinical and laboratory diagnostic approach to the detection and identification of NDM-1 and KPC carbapenemases.

1045 - 1145 Oral Presentations Session LRoom: St. Antoine B (9th floor)

Moderator: Linda ChuiL1 1045 - 1100 Seasonality of influenza-attributable

meningococcal disease in central Ontario, Canada: implications for targeting of influenza vaccination programsA TUITE, D FISMANDalla Lana School of Public Health, University of Toronto, Toronto, ON

L2 1100 - 1115 Good Coverage of Invasive Streptococcus pneumoniae

Expected for the 13-valent Pneumococcal Conjugate Vaccine (PCV-13) in CanadaHJ ADAM1,2, M DeCORBY2, NM LAING2, KA NICHOL1, AK WIERZBOWSKI2, I MARTIN3, M GILMOUR1,3, W DEMCZUK3, DJ HOBAN1,2, GG ZHANEL21Diagnostic Services of Manitoba, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB; 3National Microbiology Laboratory - Public Health Agency of Canada, Winnipeg, MB

L3 1115 - 1130 Risk of Invasive Haemophilus influenzae Type B

(Hib) Disease and Response to Hib Vaccine in Patients with Chronic Renal FailureM ULANOVA1, N HAWDON1, E NIX1, G FERRONI2, W MCCREADY11Northern Ontario School of Medicine, Thunder Bay, ON; 2Northern Ontario School of Medicine, Sudbury, ON

L4 1130 - 1145 Spatial and Temporal Distribution of Tuberculosis

in the Northwest Territories, CanadaL CHUI1,2, H LI1, C CASE3, V LI11Provincial Laboratory for Public Health, Edmonton, AB; 2Laboratory Medicine and Pathology, Edmonton, AB; 3Department of Health and Social Services, Yellowknife, Northwest Territories

1200 – 1400 Delegate Lunch (Montréal Ballroom Foyer)

Educational Program

1200 – 1400 PICNIC Meeting(Notre Dame – 3rd floor)

1200 – 1400 AMMI Canada – Communications and PR Committee Meeting(Youville – 3rd floor)


Tuberculosis: An old disease with many new twists Dick Menzies (Montréal, QC)

Objectives: • To describe the epidemiology of Drug Resistant

Tuberculosis (DR-TB) - in Canada and globally. • To describe the major methods of diagnosis of

DR-TB, including new rapid molecular methods. • To review the treatment of DR-TB including

MDR-TB, and provide some background information to recent changes in international guidelines for treatment of MDR-TB.

1515 – 1530 Break (9th floor foyer)

1530 – 1800 Special Lecture, Awards Presentations and Clinical Vignettes(Montreal Ballroom – 11th floor)

Clinical Vignettes Co-chairs: Michael Libman (Montréal, QC) Bruce Tapiero (Montréal, QC) Discussants: Gerald Evans (Kingston, ON) Richard Lalonde (Montréal, QC) Come be part of this lively and interactive session.

You will be presented with your colleagues most interesting, difficult and head scratching cases and asked to provide input to determine the right diagnosis and treatment option.

1900 – 2200 Closing Dinner Montréal Museum of Fine Arts

1200 - 1400 Merck Integrated Symposium co-developed with AMMI Canada

(Fortifications Ballroom - 9th floor) Lunch will be served Carbapenemases: Standing Trial Moderator: Michael Libman (Montréal, QC) Speakers: James Brunton (Toronto, ON) Johann Pitout (Calgary, AB) Objectives:

• Review the actual incidence of carbapenemases in Canada.


28

STUDENT POSTER PRESENTATIONS (SP1 – SP31)Room: McGill SP1 Endemic Focus of Non-Toxigenic Corynebacterium

diphtheriae Causing Cutaneous Disease in an Impoverished Urban CommunityCF LOWE1, KA BERNARD2,3, MG ROMNEY4,5

1University of Toronto, Toronto, ON; 2National Microbiology Laboratory, PHAC, Winnipeg, MB; 3University of Manitoba, Winnipeg, MB; 4University of British Columbia, Vancouver, BC; 5Providence Health Care, Vancouver, BC

SP2 Predictability of Norovirus Outbreaks Activity in AlbertaM HASING1, B LEE1, X PANG1,2

1University of Alberta, Edmonton, AB; 2Provincial Laboratory for Public Health, Edmonton, AB

SP3 A Longitudinal Study to Examine the Epidemiology of Methicillin-Resistant Staphylococcus aureus (MRSA) Contamination in the General Environment of Three Community Hospitals in OntarioM FAIRES1, D PEARL1, J WEESE1, W CICCOTELLI2,3, R SCHERTZBERG2, K STRAUS2, G ZINKEN3

1University of Guelph, Guelph, ON; 2Grand River Hospital, Kitchener, ON; 3St. Mary’s General Hospital, Kitchener, ON

SP4 SCCmec Type IV MRSA Acquisition in Hospital Settings: Portrait From a University Health Center in MontrealP MORENCY-POTVIN, D ROULEAU, M ROGER, S GAGNON, P St-ANTOINE, P LAPLANTECentre Hospitalier de l’Université de Montréal (CHUM), Université de Montréal, Montreal, QC

SP5 Nosocomial Transmission of Group B Streptococci in a Neonatal Intensive Care Unit Proven by Positive Environmental CultureA AL-MAANI1, L STREITENBERGER2, M CLARKE2, Y YAU3, D KOVACH3, R WRAY2, A MATLOW1,2

1Division of Infectious Diseases, The Hospital of Sick Children, Toronto, ON; 2Infection Prevention and Control Department, Toronto, ON; 3Division of Microbiology, The Hospital for Sick Children, Toronto, ON

SP6 Clinical and microbiologic characteristics of Stenotrophomonas maltophilia nosocomial bacteremia over an eleven year periodP NAIDU, S SMITHUniversity of Alberta Hospital, Alberta Health Services, Edmonton, AB

All posters will be available for viewing on both Thursday April 7 and Friday April 8 from 1030 – 1400.

Mc Gill Room (8th floor) Clinical Vignette Posters (CVP1 – CP3) Student Posters (SP1 – SP19) Palais Room (8th floor) Student Posters (SP15 – SP 31) Poster Presentations (P1 – P6) and (P63 – P66)Viger Room (8th floor)Poster Presentations (P7 – P29)Ramazey Room (8th floor) Poster Presentations (P30 – P52)St. Paul Room (8th floor) Poster Presentations (P53 – P 61)

Student Poster Presenters will be at their posters on Thursday April 7 to answer questions for judges and all delegates between 1030 and 1200.

Poster Presenters will be at their posters on Friday April 8 to answers questions between 1030 and 1200.

CLINICAL VIGNETTE POSTERS (CVP1 – CVP3)Room: McGill CVP1 Fever, Leukocytosis and Zoonotic Exposure –

Diagnosing LeptospirosisJ SALMON1, D WEBSTER1,2, S EL-BAILEY2

1Department of Medicine, Division of Infectious Diseases; 2Department of Medical Microbiology, Saint John Regional Hospital, Saint John, NB

CVP2 Granulomas… so evocative yet so unspecific!J FRÈRE1, F LE DEIST2, A HATAMI3, E HADDAD2, D BOURON-DAL SOGLIO4, V LAMARRE1, P OVETCHKINE1

1Infectious Diseases Division, Department of Paediatrics, 2Immunology Division, Department of Paediatrics, Dermatology Unit, Department of Paediatrics, 4Department of Histology and Pathology - CHU Sainte-Justine – Université de Montréal

CVP3 Mycobacterium celatum Skin Infection With Sporotrichoid Spread in a HIV-Negative Immunocompromised Man - Another Fishing StoryJM LEDUC, C LAVALLÉE, SF DUFRESNE, AC LABBÉ, L POIRIERDépartement de microbiologie-infectiologie, Hôpital Maisonneuve-Rosemont, Montréal, QC

Poster Presentations and Student Poster Presentations


29

SP15 Treatment Outcomes in Patients with MRSA Bacteremia Treated with Vancomycin in a Tertiary Care Academic CenterG GIRARD1, EY HE1, DJG THIRION1,2, VG LOO1, R HORN1, HG ROBSON1

1McGill University Health Centre, Montreal, QC; 2University of Montreal, Montreal, QC

SP16 Can the Clinical Outcomes Associated with Clostridium difficile Infections (CDI) Be Predicted by Bacterial Genotype and Phenotypes?S SIRARD, L VALIQUETTE, L-C FORTIERUniversité de Sherbrooke, Sherbrooke, QC

SP17 Serum Procalcitonin as a Predictor of Ventilator-Associated Pneumonia (VAP)S JOHN1, B AHMED2, L KELLEHER2, C KIM2, S ABOUANASER1, C LEE1,2


SP18 WITHDRAWNSP19 Serum Galactomannan in Cystic Fibrosis Patients

Colonized with Aspergillus SpeciesT WARREN1, Y YAU1,2, V WATERS1,2

1University of Toronto, Toronto, ON; 2Hospital for Sick Children, Toronto, ON

Room: Palais SP20 Identification of Yeast from Blood and Sterile

Fluid by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry (MALDI)J SRIGLEY1, L MONKMAN2, S BURACOND2, L DALLE VEDOVE2, C LEE1,2, D YAMAMURA1,2

1Department of Pathology & Molecular Medicine, McMaster University, Hamilton, ON; 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON

SP21 WITHDRAWNSP22 WITHDRAWNSP23 Comparison of Three Different Methods for

Detection of Shiga-Toxin producing Escherichia Coli in a Tertiary Paediatric Care CenterE VALLIERES, M ST-JEAN, F RALLUCentre Hospitalier Universitaire Ste-Justine, Microbiology Department, Montreal, QC

SP24 Peptidoglycan O-acetyltransferase as a Key Virulence Factor of Staphylococcus aureus in a Caenorhabditis elegans Host ModelD TAMBALO1, K WU1, J-A McCLURE2, J CONLY1,2, K ZHANG1,2

1University of Calgary, Calgary, AB; 2Alberta Health Services-Calgary, Calgary, AB

SP7 The Positive Clinical Impact on Staphylococcal Bacteremia by Direct mecA PCR Testing of Blood Culture BottlesB WANG1,2, P JESSAMINE1,2, M DESJARDINS1,2, B TOYE1,2, K RAMOTAR1,2

1The Ottawa Hospital, Ottawa, ON; 2The University of Ottawa, Ottawa, ON

SP8 The Impact of Nasal Carriage of Staphylococcus aureus (SA) on Bloodstream Infections (BSI) in a Large Cohort of Hemodialysis (HD) Patients in a Tertiary-Care CenterJM LEDUC1,2, AS LAPOINTE1,2, M LEBLANC1,2, AC LABBÉ1,2, K WEISS1,2

1Hôpital Maisonneuve-Rosemont, Montréal, QC; 2Faculté de médecine, Université de Montréal, Montréal, QC

SP9 Evaluation of the Microbiology of Peritoneal Dialysis-associated Peritonitis in the Northern Peritoneal Dialysis Program in SaskatoonA PABANI, S SKINNER, J BARTONUniversity of Saskatchewan, Saskatoon, SK

SP10 Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gram-negative bacilli from positive blood culturesS ABOUANASER1, K NURI1, P DRUMMOND2, L MONKMAN2, S DALE1,2, C MAIN1,2

1McMaster University, Hamilton, ON; 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON

SP11 Failure of the Modified Hodge Test (MHT) to Detect New Delhi Metallo-beta-lactamase-1 (NDM-1) CarbapenemasesJV KUS1,2, BM WILLEY1, R MELANO3, C LAROCQUE1, K PIKE1, M LUM1, S HO1, B MITCHELL1 , DE LOW3

1University Health Network/Mount Sinai Hospital Department of Microbiology, Toronto, ON; 2University of Toronto, Toronto, ON; 3Ontario Agency for Health Protection and Promotion, Toronto, ON

SP12 WITHDRAWNSP13 WITHDRAWNSP14 EmbCAB Polymorphisms in Resistant

Mycobacterium tuberculosis Strains That Lack EmbCAB306 MutationsD VOTH1, J WOLFE2, S CHRISTIANSON2, N SMART2, M SHARMA1,2

1University of Manitoba, Winnipeg, MB; 2Public Health Agency of Canada, Winnipeg, MB



30

P2 A Single Day Prevalence Survey of Antimicrobial Utilization within Selected Canadian Acute Care Hospitals: 11% Increase in Use Between 2002-2009D GRAVEL1, G TAYLOR2, A MATLOW3, J EMBIL4, E HENDERSON5, M JOHN6, L JOHNSTON7, N LE SAUX8, J EMBREE4, V ROTH9, A WONG10, L SAXINGER2, K WEISS11, Canadian Nosocomial Infection Surveillance Program1

1Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 2University of Alberta Hospital, Edmonton, AB; 3The Hospital for Sick Children, Toronto, ON; 4Health Sciences Centre, Winnipeg, MB; 5Calgary Health Region, Calgary, AB; 6London Health Sciences Centre, London, AB; 7QEll Health Sciences Centre, Halifax, NS, 8Children’s Hospital of Eastern Ontario, Ottawa, ON; 9The Ottawa Hospital, Ottawa, ON; 10Royal University Hospital, Saskatoon, SK; 11Maisonneuve-Rosemont Hospital, Montreal, QC

P3 Developing an Antifungal Prophylaxis Algorithm in High Risk Neutropenic Patients Using Surveillance of Local Invasive Fungal Disease Prevalence and Modelling Based on Published DataL SAXINGER1, S FRYTERS2, K DOUCETTE1

1University of Alberta, Edmonton, AB; 2Alberta Health Services Edmonton, Edmonton, AB

P4 Comparison of Mortality between Nosocomial and Community Acquired Febrile Neutropenia Patients Treated initially with Cefazolin and Tobramycin: Retrospective Chart ReviewM ELLIGSEN1, SAN WALKER1,2, SE WALKER1,2, F LEPIANE3, N LATHIA1,2, C De’ANGELIS1,2, A SIMOR1,2

1Sunnybrook Health Sciences Centre, North York, ON; 2University of Toronto, Toronto, ON; 3Univeristy Health Network, Toronto, ON

P5 Bordetella holmesii Bacteremia in Northern Alberta: A 5-year Case ReviewJ KANJI1, S GEE2, J AHMED-BENTLEY3, M-C LEE3, J NIGRIN3, R VERITY3, N SOLOMON1,2

1University of Alberta, Edmonton, AB; 2Provincial Laboratory for Public Health (Microbiology), Edmonton, AB; 3DYNALife Dx Microbiology Laboratory, Edmonton, AB

P6 Prosthetic Joint Infection Caused by Bordetella holmesiiS ABOUANASER1, J SRIGLEY1, L WILCOX1, J JOHNSTONE2,3

1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON; 2Department of Medicine, McMaster University, Hamilton, ON; 3Michael G DeGroote Institute for Infectious Disease Research, Hamilton, ON

SP25 A Phase II Study of 18F-Fluorodeoxyglucose in Adults with Pyogenic Vertebral Osteomyelitis using PET/CTAK CHU1,2, HR RABIN1,2, R KLOIBER1,2, J HABA1,2

1University of Calgary, Calgary, AB; 2Alberta Health Services, Calgary, AB

SP26 WITHDRAWNSP27 I Get By With A Little Help from My Friends –

Peer Teaching Of Antimicrobial Treatment Options in Medical SchoolC BELOZER, S FORGIEUniversity of Alberta, Edmonton, AB

SP28 Not a Jedi Yet, but Not a Padawan either: Near-Peer Teaching of MicrobiologyW CHAN, S FORGIEUniversity of Alberta, Edmonton, AB

SP29 Envisioning a New Curriculum for Post Graduate Microbiology ProgramsJ NADARAJAH, A SIMOR, T MAZZULLI, L MATUKASUniversity of Toronto, Toronto, ON

SP30 First Report of Xenophilus aerolatus Causing Clinical Infection in a Patient with CAPD PeritonitisN THAMPI1, K BERNARD2, B NG2, E HARVEY1, Y YAU1

1The Hospital for Sick Children, Toronto, ON; 2National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

SP31 First Report of Isolation and Characterization of Pigmentiphaga daeguensis from a Clinical SampleN BRIDGER1,2, T BURDZ3, D WIEBE3, K BERNARD2,3

1Department of Paediatrics and Child Health, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB; 3Special Bacteriology Section, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

POSTER PRESENTATIONS (P1 – P66)Room: Palais P1 Impact of 2009 Capital Health Vancomycin

Monitoring and Dosing Guidelines on Clinical PracticeT ELTON1, M GRAY1, L SAXINGER2, P MAYO1, S KOSHMAN1,2

1Alberta Health Services, Edmonton, AB; 2University of Alberta, Edmonton, AB



31

P14 Rapid and Accurate Diagnosis of Clostridium difficile InfectionHR DEVLIN1,2, C JACKSON1, O PANGAN1, G BROUKHANSKI2,3, D PILLAI2,3

1Dept of Laboratory Medicine and Keenan Research Centre of the LiKa Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON; 2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; 3Ontario Agency for Health Protection and Promotion, Toronto, ON

P15 Evaluation of a Commercial Kit the Illumigene DNA Amplification Assay to Detect Clostridium difficile Against In-house Developed RT-PCR MethodS JOHN1,2, L MONKMAN1, C LEE1,2, P JAYARATNE1,2

1Hamilton Regional Laboratory Medicine Program-Hamilton Health Sciences and St. Joseph’s Healthcare, Hamilton, ON; 2McMaster University, Hamilton, ON

P16 Comparison of Test Performance Characteristics of an In-house Real-Time Multiplex PCR Method with Commercial PCR Assays for Detection of Toxigenic C. difficile from Adult StoolsP JAYARATNE1,2, L MONKMAN1, B AHMED1, G BROUKHANSKI3,4, DR PILLAI3,4, C LEE1,2

1Hamilton Regional Laboratory Medicine Program - Hamilton Health Sciences and St. Joseph’s Healthcare, Hamilton, ON; 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON; 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; 4Ontario Agency of Public Health Protection and Promotion, Toronto, ON

P17 Prevention of Clostridium difficile Infections by Bio-K+CL1285®: Explanation of Some Mechanisms of ActionM MILLETTE, M FRAPPIER, G ST-PIERRE, É SIMARD, S CARRIÈREBio-K+ Pharma, Laval, QC

P18 Differentiation of members of the Mycobacterium tuberculosis complex using a Luminex assayJ WOLFE1, M SHARMA1,2, S CHRISTIANSON1

1Public Health Agency of Canada, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB

P19 Comparison of Dip N Count to Sterile Plastic Containers for Urine TransportC VERMEIREN1,2, L BISHOP1, K KATZ1,2,3

1Shared Hospital Laboratory, Toronto, ON; 2University of Toronto, Toronto, ON; 3North York General Hospital, Toronto, ON

Room: Viger P7 Desulfovibrio spp. Bacteremia Associated with

Underlying Gastrointestinal IllnessesN MINA1, F SHING2, P KIBSEY3,4, D PURYCH4,5, T RAHIM2, D ROSCOE4,6, L HOANG2,4

1University of Alberta, Edmonton, AB; 2BCCDC Public Health and Reference Microbiology Laboratory, PHSA, Vancouver, BC; 3Royal Jubilee Hospital, Victoria, BC; 4UBC Dept of Pathology and Laboratory Medicine, Vancouver, BC; 5Royal Columbian Hospital, New Westminister, BC; 6Vancouver General Hospital, Vancouver, BC

P8 Actinomycete Bacteremia Caused by Saccharopolyspora sp.C TURENNE1, J DELPORT2, T BURDZ3, D WIEBE3, D THIRY1, N ANTONISHYN1, E NAGLE1, P LEVETT1, GB HORSMAN1, K BERNARD3

1Saskatchewan Disease Control Laboratory, Regina, SK; 2Regina General Hospital, Regina, SK; 3National microbiology Laboratory, Public Agency of Canada, Winnipeg, MB

P9 Pseudallescheria boydii Wrist Septic Arthritis/Osteomyelitis in a Patient with Rheumatoid Arthritis Receiving EtanerceptJ KANJI, J FULLER, S SMITH, L MIEDZINSKIUniversity of Alberta, Edmonton, AB

P10 Anidulafungin for treatment of Invasive Candidiasis/Candidemia: A Tertiary Center Canadian ExperienceS HAIDER, A BROOKSMcMaster University, Hamilton Health Sciences, Hamilton, ON

P11 Detection of Shiga Toxin-Producing E. coli (STEC) using Enzyme-Linked Immunosorbent Assay and Real-time PCRL CHUI1,2, P KWONG1

1Provincial Laboratory for Public Health, Edmonton, AB; 2Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB

P12 A Review of a New Two Step Algorithm to Detect Toxigenic Clostridium difficileJ KRAMER, L FEDIRKO, L DAWSONRegina Qu’Appelle Health Region, Regina, SK

P13 Evaluation of Techlab QUICK CHEK™-60 glutamate dehydrogenase test for detection of Clostridium difficile in clinical specimensG BROUKHANSKI1,2, A MAKI1, A PERALTA1, DR PILLAI1,2

1OAHPP, PHL-Toronto, Toronto, ON; 2LMP, U of Toronto, Toronto, ON


32


32

P20 Evaluation of a New Health Canada-approved Lyme Immunoblot Assay for Confirmation of Positive EIA Screen ResultsK KADKHODA, P VAN CAESEELE, G SMART, W MARCadham Provincial Laboratory, Winnipeg, MB

P21 Comparison of Eluted Swab and Amies Charcoal Swab for Determination of Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE) Colonization and if Nasal Swab Culture alone is Sufficient for Detection of MRSA Colonization in Hospitalized PatientsS JOHN1, B AHMED2, L KELLEHER2, C KIM2, R ONISHI2, B MACORETTA2, C LEE1,2


P22 Comparison of Pooled eSwabs to Swabs in Amies Transport Medium (ATM) for Detecting Epidemiologically Significant Organisms (ESO) from Surveillance in Emergency Room (ER) and Inflammatory Bowel Disease (IBD) PatientsBM WILLEY1, P GNANASUNTHARAM1, G NGUYEN1,2, B BORGUNDVAAG1,2, W LEUNG1,2, M LOFTUS1, R THANABALAN1, V PORTER1, G SMALL1, IA EDWARDS1, P LO1, K WONG1, G MAHLI1, AJ MCGEEER1,2, SM POUTANEN1,2


P23 Clinical Evaluation of Five Chromogenic Selective Agar Formulations for the Detection of VanB-mediated ResistanceJ FULLER, L TURNBULLUniversity of Alberta Hospital, Edmonton, AB

P24 Retrospective Evaluation of Oxoid Brilliance VRE® and Bio-Rad VRESelect® Chromogenic Agars for Detection of Vancomycin-Resistant Enterococci (VRE) using a Genetically Diverse Isolate CollectionBM WILLEY1, P GNANASUNTHARAM1, L LOUIE2, K PRAYITNO3, T FUNG3, P GNANASUNTHARAM1, P LO1, AJ MCGEER1,3, SM POUTANEN1,3

1Mount Sinai Hospital/University Health Network, Toronto, ON; 2Sunnybrook Health Sciences Centre, Toronto, ON; 3University of Toronto, Toronto, ON

P25 Prospective Comparison of Oxoid Brilliance VRE® and Bio-Rad VRESelect® to Non-Chromogenic Agars for Detecting Vancomycin-Resistant Enterococci (VRE) from Surveillance SpecimensBM WILLEY1, L LOUIE2, P GNANASUNTHARAM3, T FUNG3, C WATT2, P GNANASUNTHARAM1, C VERMEIREN4, G RICCI5, P LO1, K WONG1, A SIMOR2, AJ MCGEER1,2, T MAZZULLI1,2, SM POUTANEN1,2

1Mount Sinai Hospital/University Health Network, Toronto, ON; 2Sunnybrook Health Sciences Centre, Toronto, ON; 3University of Toronto, Toronto, ON; 4Shared Hospital Laboratory, Toronto, ON; 5William Osler Health Sciences Centre, Toronto, ON

P26 Evaluation of Three Chromogenic Media for Detection of Vancomycin-Resistant Enterococci in a Tertiary-Care HospitalM MILLER2, D ZOUTMAN1,2, L TOMALTY1,2, D ARMSTRONG2, J DIEN BARD1,2

1Queen’s University, Kingston, ON; 2Kingston General Hospital, Kingston, ON

P27 Biofilm Susceptibility of P.aeruginosa Isolated From Patients with Otitis Media to Ciprodex, Ciprofloxacin and N-acetylcysteineM NOBLE1, V RESTELLI1, R RENNIE1,2, B WESTERBERG1, L TURNBULL1,2

1University of British Columbia, Vancouver, BC; 2University of Alberta, Edmonton, AB

P28 Screening possible Candida albicans isolates for Candida dubliniensis: is it worth it?D HALDANE1Queen Elizabeth II Health Sciences Centre, Halifax, NS; 2Dalhousie University,

P29 Evaluation of Vitek-2 (VT2) YS01 Antifungal Susceptibility Testing (AFST) in Candida speciesBM WILLEY1, K PRAYITNO2, A GELOSIA1, C PORTER1, J FULLER3, SM POUTANEN1,2

1Mount Sinai Hospital/University Health Network, Toronto, ON; 2University of Toronto, Toronto, ON; 3University of Alberta Hospital, Edmonton, AB

Room: Ramazey P30 Determining Presence of Broad Spectrum Beta-

Lactamases in Enterobacteriaceae- Comparison of the MAST Disc Method to Standard Phenotypic and Molecular Detection MethodsM HOOPER1, V HADW ELL2, L HOANG3,4, A BALBIRNIE5, E BLONDEL-HILL2,3

1University of Victoria, Victoria; 2Kelowna General Hospital, Kelowna; 3University of British Columbia; 4BC Centre for Disease Control, Vancouver, BC; 5Simon Fraser University, Burnaby, BC



33

P36 Validation of Etest Gradient Strips for Daptomycin (DAP) MIC Determination in Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus and Coagulase-Negative Staphylococci (MRSA, MSSA, CNST)BM WILLEY1, B MINNEMA2, P GNANASUNTHARAM1, A GELOSIA1, N KREISWIRTH1, DE LOW1,2, K WONG1,2, SM POUTANEN1


P37 The Incidence of Multi-drug Resistance Acinetobacter Bumannii and Its Involvement in Hospital Infections: One Year Prospective StudyM HALWANI, K AL-HARTHI, NA RASINThe Infection Control Sterilization and Medical Waste Management Program, Health Affairs, Jeddah, Saudi Arabia

P38 Surveillance of gram-negative intra-abdominal and urinary tract pathogens in Edmonton, Alberta, 2008-2010: the SMART StudyR RENNIE1, LA TURNBULL1, A JOHNSON2

1University of Alberta Hospital, Edmonton, AB; 2IHMA, Schaumburg, Il, United States

P39 Two Cases of Significant Adverse Patient Events Due to Contact Isolation Precautions in Ambulatory Care Programs - Time to Reassess Evidence and PoliciesL SAXINGER, G TAYLORUniversity of Alberta, Edmonton, AB

P40 Efficacy of alcohol-based hand hygiene on spore-forming bacteria in a community hospital intensive care unitM KELLY, M DELORME, W DANDJINOUHôpital Jean Talon, Montréal, QC

P41 Hey Baby What’s Your Sign? Educational Infection Control Signs in a Canadian Paediatric Acute Care HospitalS FORGIE1,2, J DURAND1, S GILBRIDE1, S WELLING1

1Stollery Children’s Hospital, Edmonton, AB; 2University of Alberta, Edmonton, AB

P31 Detection of prolyliminopeptidase-negative Neisseria gonorrhoeae strains in QuébecB LEFEBVRE1, F LAMOTHE2, M MILLER3, C FORTIN4, I MARTIN5, LK NG5, A-M BOURGAULT1

1Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC; 2CHUM-Hôpital St-Luc, Montréal, QC; 3Hôpital général juif S.M.B.D., Montréal, QC; 4CHUM-Hopital Notre-Dame, Montréal, QC; 5National Microbiology Laboratory, Winnipeg, MB

P32 Evaluation of the Multi-Locus Variable Number Tandem Repeat Analysis (MLVA) PulseNet Protocol for Typing Salmonella EnteritidisAK KEARNEY1, L HOANG2,3, M TAYLOR4, E GELANIS4,5, A G ERBASI1, M GILMOUR1,6

1National Microbiology Laboratory, Winnipeg, MB; 2BCCDC Public Health and Reference Microbiology Laboratory, PHSA; 3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 4BC Centre for Disease Control; 5University of British Columbia, Vancouver, BC; 6Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB

P33 Genetic Heterogeneity of Community Associated Methicillin-Resistant Staphylococcus aureus in SaskatchewanPN LEVETT1, RR McDONALD1, E NAGLE1, CE WONG1, MR MULVEY2, GB HORSMAN1 1Saskatchewan Disease Control Laboratory, Regina, SK; 2National Microbiology Laboratory, Winnipeg, MB

P34 Characterization of Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Canadian Patients with Bloodstream Infection(BSI)A MOUNCHILI1, A SIMOR2, D GRAVEL1, M MULVEY3, E BRYCE4, M LOEB5, A MATLOW6, AJ MCGEER7, L LOUIE2, C WATT2, J CAMPBELL3, Canadian Nosocomial Infection Surveillance Program1

1Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 2Sunnybrook Health Sciences Centre, Ottawa, ON; 3National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 4Vancouver General Hospital, Vancouver, BC; 5Hamilton Health Sciences Corporation, Hamilton, ON; 6Hospital for Sick Children, Toronto, ON; 7Mount Sinai Hospital, Toronto, ON

P35 Surveillance for community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strains isolated from blood cultures in QuébecS LÉVESQUE1, B LEFEBVRE1, L-A GALARNEAU2, A-M BOURGAULT1

1Laboratoire de santé publique du Québec/Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC; 2Centre hospitalier de Trois-Rivières, Trois-Rivières, QC



34

P47 Modelling of Laboratory Testing for an Influenza Pandemic: Evaluation of a Model using Real-time Data for Ontario from the Second Wave 2009 H1N1 PandemicK MINNINGS1, A KOU1, G EVANS1,2, T DAY1, A MAJURY1,2

1Queen’s University, Kingston, ON; 2Ontario Agency for Health Protection and Promotion, Kingston, ON

P48 Frequent Detection of Rhinovirus/Enterovirus Amongst Children Hospitalized with Respiratory InfectionS MATHUR1, J BABWAH2, S CHONG2, J MAHONY1, M SMIEJA1

1McMaster University, Hamilton, ON; 2St. Joseph’s Healthcare, Hamilton, ON

P49 Evaluation of the Seeplex® RV12 Multiplex PCR Assay for the Detection of Common Respiratory VirusesC KERN1, L SHAW1, L SULLIVAN1, T KARNAUCHOW1,2

1Regional Virology Laboratory, Children’s Hospital of Eastern Ontario, Ottawa, ON; 2University of Ottawa, Ottawa, ON

P50 Development of a Multiplex Respiratory Virus Real Time RT-PCR Designed to Replace Traditional Detection Methods in a Regional Virology LaboratoryC RUTHERFORD1,2, SE DALE2,3, D JOHNSON1,2, M MACPHERSON1,2

1St. Joseph’s Healthcare, Hamilton, ON; 2Hamilton Regional Lab Medicine Program, Hamilton, ON; 3McMaster University, Hamilton, ON

P51 Comparative Evaluation of the Luminex xTAG RVP Fast and the QIAGEN Resplex II v.2 Assays for Respiratory Virus DetectionJ MÉNARD, H CHARESTLaboratoire de santé publique du Québec/INSPQ, Sainte-Anne-de-Bellevue, QC

P52 Evaluation of Copan UTM-RT transport medium and Sigma VCM medium for the recovery of cultivatable, clinical virus isolates and comparison of the Copan flocked swab with the Sigma swab for specimen collectionK BRANDT, PN LEVETT, GB HORSMANSaskatchewan Disease Control Laboratory, Regina, SK

P42 Personal Protective Equipment Use among Canadian Healthcare Workers during the Delivery of Care to Patients on Droplet PrecautionsR MITCHELL1, V ROTH2, G ASTRAKIANAKIS3, E BRYCE4, R GERVAIS1, D GRAVEL1, L JOHNSTON5, G TAYLOR6, M VEARNCOMBE7, K WILKINSON1, Canadian Nosocomial Infection Surveillance Program1

1Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON; 2The Ottawa Hospital, Ottawa, ON; 3University of British Columbia, Vancouver, BC; 4Vancouver General Hospital, Vancouver, BC; 5Queen Elizabeth II Health Sciences Centre, Halifax, NS; 6University of Alberta Hospital, Edmonton, AB; 7Sunnybrook Health Sciences Centre, Toronto, ON

P43 Seroconversion after one dose of adjuvanted pH1N1 influenza vaccine in solid organ transplanted (SOT) patientsM RESENDE1,2, S HUSAIN1, C ROTSTEIN1

1University of Toronto, Toronto, ON; 2University of Campinas, Campinas, SP, Brazil

P44 Production of Standardized Control Samples for Assessing Intra- and Inter-Laboratory Variability of Influenza RT-PCR Detection Tests During the 2009 A(H1N1) Influenza (pH1N1) PandemicH CHAREST, É BÉLANGER-TRUDELLE, M LORTIE, M FAUVEL, M COUILLARDLaboratoire de santé publique du Québec/INSPQ, Sainte-Anne-de-Bellevue,Qc

P45 Respiratory Infections in Institutions during the Second Wave of Pandemic (H1N1) 2009A MARCHAND-AUSTIN1, N LOMBARDI2, A ESHAGHI2, E LOMBOS2, D ALEXANDER2,3, S PATEL2,3, J LONGTIN2, E KRISTJANSON2, F JAMIESON2,3, D LOW2,3,4, J GUBBAY2,3

1Public Health Agency of Canada, Winnipeg, MB; 2Ontario Agency for Health Promotion and Protection, Toronto, ON; 3University of Toronto, Toronto, ON; 4Mount Sinai Hospital, Toronto, ON

P46 Multidrug-Resistant Pandemic Influenza A (H1N1) Infection in an Immunocompetent Ambulatory Child with no Prior Antiviral ExposureA ESHAGHI1, S PATEL1,2, A SARABIA3, R HIGGINS1, A SAVCHENKO2, P STOJIOS2, Y LI4, N BASTIEN4, D ALEXANDER1,2, D LOW1,2,5, J GUBBAY1,2,5,6

1Ontario Agency for Health Protection and Promotion, Toronto, ON; 2University of Toronto, Toronto, ON; 3The Credit Valley Hospital, Mississauga, ON; 4Public Health Agency of Canada, Winnipeg, MB; 5Mount Sinai Hospital, Toronto, ON; 6The Hospital for Sick Children, Toronto, ON



35

P61 A Review of the Current NLHRS HTLV Serology Confirmatory Algorithm in Identifying HTLV-II Antibody Positive SamplesL MALLOCH, J KIMPHAC, Ottawa, ON

Room: Palais P62 Metagenomic Insights: Public Health Risk

Potential of Six Untreated Water SamplesN PRYSTAJECKY1,2, J GARDY2,3, M GRAHAM4,5, K JEWELL1, V WOLF4, T MURPHY4, S TYLER4, J ISAAC-RENTON1,2, P TANG1,2

1British Columbia Centre for Disease Control Public Health and Reference Laboratory (BCPHL), Vancouver, BC; 2University of British Columbia, Vancouver, BC; 3British Columbia Centre for Disease Control (BCCDC), Vancouver, BC; 4National Microbiology Laboratory, Winnipeg, MB; 5University of Manitoba, Winnipeg, MB

P63 Rural Well Water Contamination and Human Health: an Investigation in Eastern OntarioD RYDING1, G EVANS1,2, K MOORE1,3, A VANDIJK3, A MAJURY1,4

1Queen’s University; 2University Hospitals Kingston; 3KFL&A Health Unit, Kingston; 4Ontario Agency for Health Protection and Promotion, Toronto, ON

P64 Comparative Evaluation of Puritan and Copan Liquid Amies Transport Systems for the Recovery of Streptococcus pneumoniae against the CLSI M40A StandardB GANDHI1, T MAZZULLI1,2

1Department of Microbiology, Mt. Sinai Hospital and University Health Network, Toronto, ON; 2University of Toronto, Toronto, ON

P65 Incidence of Invasive Aspergillosis and Antifungal Use Following Implementation of Galactomannan in a High Risk Hematology Population Using the 2008 EORTC CriteriaC BEAUCHAMP-PAYMENT1, M DJADI1, DJG THIRION1,2, DC SHEPPARD3, Y ROUSSEAU1, S CARLE1, C DUPONT1, G POPRADI1, A BONNICI11McGill University Health Centre, Montreal, QC; 2University of Montreal, Montreal, QC; 3McGill University, Montreal, QC

P66 Maraviroc Mediated CCR5 Blockage for HIV Infected Individuals is Associated with Increased Rates of Respiratory Tract InfectionsY KEYNAN1,2,3, E RUBENSTEIN1,2, K KASPER1,2, K FOWKE1,3

1University of Manitoba, Department of Medical Microbiology, Winnipeg, MB; 2University of Manitoba, Department of Internal Medicine, Winnipeg, MB; 3University of Manitoba, Department of Community Health Sciences, Winnipeg, MB

Room: St. Paul P53 Comparison of DNA and RNA HPV Detection

Assays on Cervical, Vaginal and Urine SpecimensM CHERNESKY, A LYTWYM, D JANG, M HOWARD, L ELIT, K ONUMA, M KLINGEL, J GILCHRIST, A ECOBICHON-MORRISMcMaster University, Hamilton, ON

P54 Validation of Real-Time RT-PCR for Molecular Detection of Rubella VirusR WEBER, J HIEBERT, A SEVERININational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

P55 Measles Outbreak-Post-Olympics-2010K GUNADASA1, A MAK1, P TANG1, J BEIRNES2, G TIPPLES2, M KRAJDEN1, M PETRIC1, Y CHANG11BC Centre for Disease Control, Vancouver, BC; 2National Microbiology Laboratory, Winnipeg, MB

P56 A Review of Laboratory Testing During a Mumps OutbreakJ GUBBAY1,2, K OGBULAFOR1, E LOMBOS1, R HIGGINS1, A ESHAGHI1, D ALEXANDER1,2, E KRISTJANSON1, S RACEY1, J MAREGMEN1, G LIM1, S PATEL1,2, G TIPPLES3, D LOW1,2,4, S DEEKS1,2, T MAZZULLI1,2,41Ontario Agency for Health Protection and Promotion, Toronto, ON; 2University of Toronto, Toronto, ON; 3National Microbiology Laboratory, Winnipeg, MB; 4Mount Sinai Hospital, Toronto, ON

P57 Evaluation and Verification of the Seeplex® Multiplex Viral Diarrhoea Panel for the Simultaneous Detection of Rotavirus, Adenovirus, and Norovirus in Clinical Stool SpecimensR HIGGINS, M CARDONA, S MASNEY, M BENIPRASHAD, A ESHAGHI, J GUBBAY1Ontario Agency for Health Protection and Promotion, Toronto, ON; 2University of Toronto, Toronto, ON

P58 A Review of Ten Years of Hepatitis C Genotyping in New Brunswick: 2000-2009R GARCEAU, G GIROUARD, L THIBAULT, M MALLETHôpital Dr G.L. Dumont, Moncton, NB

P59 Complete Genome Sequencing of Two Coxsackie A9 Virus Isolates to Assess Recombination Events and Genetic DriftK PABBARAJU1, S WONG1, R TELLIER1,21Provincial Laboratory for Public Health, Calgary, AB; 2Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB

P60 Evaluation of the Focus Diagnostic HerpeSelect 1 and 2 ELISA IgGA MAK1, M PETRIC1,2, M KRAJDEN1,2, A SEVERNINI31PHSA Laboratory, BCCDC, Vancouver, BC; 2University of British Columbia, Vancouver, BC; 3National Microbiology Laboratory, Winnipeg, MB



36

Closing Dinner at the Montréal Museum of Fine Arts

Wine sponsored by

Special ExhibitThe Warrior Emperor and China’s Terracotta ArmyThis is a once in a lifetime opportunity to view priceless treasures from one of the most important archaeological sites in the world. It will take visitors on a faraway journey covering 1,000 years of Chinese history.

Date: Saturday April 9Time: 1900 – 2200Cost: $65.00 (5%GST)

Unarmoured high-ranking officer EarthenwareQin dynasty, 221-206 BCExcavated in 1980 at Terracotta Army Pit No. 1Lintong, Shaanxi provinceEmperor Qin Shihuang’s Terracotta Army Museum, 002743© Shaanxi Provincial Cultural Relics Bureau and the Shaanxi Cultural Heritage Promotion Centre, People’s Republic of China, 2009.


37

Devlin HR P14Dextras P F5Dhaliwal S A6Dimitrova K H5,H6Dines I K2Djadi M P65Donaldson T A1Doucette K P3Douglas L F4Dowhaniuk D C2Drebot MA H5,H6Dreher K A2,A3Drews S F4,K4Drummond P SP10Dufresne SF CVP3Dumonceaux T B3Dupont C P65Durand J P41

EEcobichon-Morris A P53Edwards IA P22El-Bailey S CVP1Elit L P53Elligsen M P4Elton T P1Embil J E2,P2Embree J D1,E3,P2Eshaghi A P45,P46,P56,P57Eskandarian S B7Evans G P47,P63Fagan A A1

FFaheem A D3Faires M SP3Fast M A1Fauvel M P44Fearon M K2Fedirko L P12Fernandez E B7Fernando K K4Ferroni G L3Fisman D D6,L1Fleming CA C1Flynn G C1Forgie S P41,SP27,SP28Fortier L-C SP16Fortin C P31Fowke K P66Franco E B2Frappier M P17Frenette C I3Frère J CVP2Frost EH F5Fryters S P3Fuller J P9,P23,P29,D4,F3Fung T C3,P24,P25

GGagnon S SP4Galarneau L-A P35Gandhi B P64Garber G G4Garceau R P58Gardy J P62Gee S P5Gelanis E P32Gelosia A D3,P29,P36Gerbasi A P32Gervais R G5,G6,P42Ghosh C C2Gilbride S P41Gilchrist J B1,P53Gill KL B4Gilmour M H2,L2,P32Girard G SP15Girouard G P58Gnanasuntharam P D3,P22, P24,P25,P36Goleski V B3Graham M H2,P62Granados A G2Gravel D A4,D1,E2,E3,G5,I3, P2,P34,P42,G6Gray M P1Grice D K1Gubbay J G3,P45,P46,P56,P57Gunadasa K P55Gun-Munro J C1Guzman M C2

HHaba J SP25Haddad E CVP2Hadwell V D2,P30Haider S E5,J4,P10Haldane D P28Halwani M P37Hamilton K B7Hamula C F1Hansen G A1Hao W H1Harroun N B1Harvey E SP30Hasing M SP2Hatami A CVP2Hawdon N L3Hayes T G4He EY SP15Hemmons P H2Henderson E P2Henry B K4Hiebert J P54Higgins R P46,P56,P57Ho S SP11Hoang L E4,H4,J3,P7,P30,P32Hoban DJ E1,L2

Authors Index

AAbouanaser S P6,SP10,SP17Adam HJ E1,L2Ahmed B J4,P16,P21,SP17Ahmed R D5Ahmed-Bentley J P5Alawi M J4Alexander D H1,P45,P46,P56Alfa M C6Al-Harthi K P37Al-Maani A SP5Allen V H2Almohri H J1,J2Al-Rawahi G A6Amihod B I3Andonov A I1Andonova M H5,H6Antonishyn N P8Armstrong D P26Arora A G2AstraKianakis G G5,G6,P42Auk B D4

BBabwah J P48Baker R K4Balbirnie A H4,P30Balfour L G4Barclay R A1Bard JD P26Barton J SP9Bastien N P46Beauchamp-Payment C P65Bechard C J1Beirnes J P55Bélanger-Trudelle É P44Béliveau C B6Belozer C SP27Beniprashad M P57Beresford N C3Bernard K E4,H3,P8,SP1 SP30,SP31Biers K B1Bilawka J C4Bishop L P19Bittante J J2Blondel-Hill E A2,A3,D2,P30Bonnici A P65Borgundvaag B P22Boss S J2Bourgault A-M B6,P31,P35Bouron-Dal Soglio D CVP2Bowes V K4Bowie W A2,A3,A5Boyd D D1,E3Brandt K P52Bridger N SP31Brooks A E5,P10

Broukhanski G P13,P14,P16Brown K D6Brown SZ K1Bryce E A4,D1,E3,G5,G6,P34,P42Bunzeluk K A1Buracond S SP20Burdz T E4,H3,P8,SP31

CCampbell J P34Canadian Nosocomial Infection Surveillance Program A4,E2, G5,G6,P2,P34,P42Cantin R F6Cardona M P57Carle S P65Carranza D J3Carrière S P17Case C L4Castro M J3Ceballos K B2Champagne S C4Chan W SP28Chang Y P55Charest H B6,F6,P44,P51Chernesky M B1,P53Childerhose L B7Chong M A2,A3,A5Chong S G2,P48Christianson S P18,SP14Chu AK SP25Chui L D5,F3,F4,L4,P11Ciccotelli W SP3Clarke M SP5Coldman A B2Comité Sur Les Infections Nosocomiales Du Québec P33Conly J E2,SP24Cook D B2Corace K G4Couillard M B6,P44Cross C H2

DDale SE P50,SP10Dalle Vedove L SP20Daly J J3Dandjinou W P40Dawson L P12Day T P47De’angelis C P4Decorby M E1, L2Deeks S P56Delorme M P40Delport J P8Demczuk W L2Der E D5Desjardins M C1,C5,SP7Deslandes S F5


38

Lowe CF SP1Luinstra K G2Lum M SP11Lytwym A P53

MMa J H1Macoretta B P21Macpherson M P50Mahli G P22Mahony J G2,P48Main C SP10Majury A P47,P63Mak A G1,P55,P60,P13Makowski K H5,H6Malejczyk K F3Mallet M P58Malloch L P61Malott S J3Man S H4,K3,K4Manickam K C6Mar W P20Marchand-Austin A G3,P45Maregmen J P56Marra F A2,A3,A5Martin I L2,P31Martinez L A6Masney S P57Mason A I1Mataseje LF D1, E1,E3Mathur S P48Matisz C K1Matlow A A4,E2,P2,P34,SP5Matukas L SP29Mayo P P1Mazzocco A J3Mazzulli T P25,P56,P64,SP29Mccarthy A G4Mcclure J-A SP24Mccready W L3Mcdonald RR P33Mcgeer A A4,C3,D3,I3, P24,P22,P25, P34Mckay R A2,A3,A5Meaney H C1Mei W B2Melano R SP11Ménard J P51Miedzinski L P9Miller M P26,P31Millette M P17Mina N E4,P7Minnema B P36Minnings K P47Mitchell B SP11Mitchell R E2,G5,G6,I3,P42Mithani S H4Monkman L P15,P16,SP10,SP20Moore D I3

Moore K P63Moreau D D5Morency-Potvin P SP4Morshed MG H4,K3,K4Mounchili A A4,D1,E3,P34Mubareka S G2Muller M D3Mulvey M A4,D1,E1,E2,E3, P33,P34Murphy D I1Murphy T P62

NNadarajah J SP29Nagle E P8,P33Naidu P K1,SP6Ndao M K2Ng B H3,SP30Ng H C3Ng LK P31Ng W D3Nguyen G P22Nichol KA L2Nigrin J P5Nix E L3Noble M P27Nuri K SP10

OOgbulafor K P56Ogilvie G B2Onishi R P21Onuma K P53Ormiston D E2Ostrowska K D3Ovetchkine P CVP2

PPabani A SP9Pabbaraju K B4,P59Paccagnella A J3Pacheco AL H3Pagotto F H2Palmay L E6Pang X SP2Pangan O P14Patel S G3,P45,P46,P56Patrick D A2,A3,A5Pearl D SP3Peralta A P13Petric M G1,P55,P60Petrich A G2Pienaar C A6Pike K SP11Pillai DR P13,P14,P16Pizarro R C2Poirier L CVP3Poliquin M I1Pong-Porter S C3

Holloway K H5,H6Holtslander B J3Hooper M D2,P30Horn R SP15Horsman GB P8,P33,P52Houston S K1Howard M P53Huang M K2Husain S P43Hydesmith E A1

IIsaac-Renton J D4,K3,P62

JJackson C P14Jalo I I4Jamieson F C1,G3,H1,P45Jang D B1,P53Jang W C4Jayaratne P P15,P16Jessamine K C5Jessamine P SP7Jewell K P62John M P2John S J4,P15,P21,SP17Johnson A P38Johnson D P50Johnson R J3Johnston L E2,G5,G6,P2,P42Johnstone J P6

KKadivar K B5Kadkhoda K H5,H6,P20Kanji J I2,P5,P9Kapala J B1,C2Karlowsky JA E1Karnauchow T P49Kasper K P66Katz K C1,D3,P19Kearney AK P32Kelleher L P21,SP17Kelly M A6,J2,P40Kern C P49Keynan Y P66Kibsey P D1,E3,P7Kim C J4,P21,SP17Kim J B5,P61Klingel M P53Kloiber R SP25Kornherr P C2Koshman S P1Kou A P47Kovach D SP5Kowalewska-Grochowska K K1Krajden M B2,G1,P55,P60Kramer J P12Kreiswirth N P36

Krinke V K1Kristjanson E P45,P56Kuhn M D1,E3Kunimoto D D5Kus JV SP11Kwong P P11

LLabbé AC SP8,CVP3Lagace-Wiens P E1,C6Laing NM L2Lamarre V CVP2Lamirande R B6Lamothe F P31Laplante P SP4Lapointe AS SP8Larocque C C3,SP11Laryea K A1Lathia N P4Lavallée C CVP3Lawoyin T I4Le C F1Le Deist F CVP2Le Saux N P2Leblanc M SP8Leduc JM SP8,CVP3Leduc S E2,G5,G6Lee B SP2Lee C J4,P15,P16,P21,SP17,SP20Lee M-C F3,P5,H4,K3,K4Lefebvre B P31,P35Lepiane F P4Leung W P22Lévesque S P35Levett P P8Levett PN H5,P33,P52Lewis L C2Lewis T C5Li H L4Li V L4Li X F1Li Y P46Lim G P56Lin L I1Lo P C3,P22,P24,P25Lo T K3,K4Loeb M A4,B7,P34Loftus M P22Lombardi N P45Lombos E G3,P45,P56Longtin J G3,P45Loo VG SP15Lorenzana I B7Lortie M P44Louie L D3,F2,G2,P24,P25,P34Lovagi G A1Low D G3,H1,P36,P45,P46, P56,SP11Low DE P36,SP11

Authors Index


39

VValiquette L SP16Vallieres E SP23Van Caeseele P H5,H6,P20Van Domselaar G H2Van Niekerk D B2Vandijk A P63Vaudry W I2Vearncombe M G2,G5,G6,P42Verity R P5Vermeiren C P19,P25Vernich L D3Voth D SP14

WWalker I J4Walker M H2Walker SAN E6,P4Walker SE E6,P4Walkty A E1Wang B SP7Warren K H1Warren T SP19Waters V SP19Watt C P25,P34Weber R P54Webster D CVP1Weese J SP3Weir C G6Weiss K P2,SP8Welling S P41Westerberg B P27Wiebe D E4,H3,P8,SP31Wierzbowski AK L2Wilcox L P6

Wilkinson K G5,I3,P42Willey BM C3,P22,P24,P25, P29,P36,SP11Wolf V P62Wolfe J P18,SP14Wong A C4,E2,I3,P2Wong B D4Wong CE P33Wong H D3,G2Wong J D4Wong K P22,P25,P36Wong M J2Wong Q H4,K3,K4Wong S B4,P59Wong T A6,J3Wray R SP5Wu K SP24

YYamamura D J4,SP20Yanow SK K1Yau Y SP19,SP30Yau YCW SP5Yeboah A C3Yow O G2

ZZahariadis G F4Zhanel GG E1,L2Zhang K SP24Ziegler J H2Zinken G SP3Zoutman D E2,P26

Popradi G P65Porter C P29Porter V P22Poutanen SM C1,C3,P22,P24, P25,P29,P36Prayitno K C3,P24,P29Prematunga C G4Prystajecky N D4,P62Purych D P7

RRabin HR SP25Racey S P56Rahim T P7Rai JS E4Rallu F SP23Ramotar K SP7Rasin NA P37Rawte P G3Raymondo D C1Reimer A H2,H3Rennie R P27,P38Resende M P43Restelli V P27Reyes R A6Ricci G P25Richardson D D3Richardson SE J3Ritchie G C4,J2Robson HG SP15Roger M SP4Romano P J1Romney MG C4,SP1Roscoe D D1,E3,P7Roth V G4,G5,G6,P2,P42Rotstein C P43Rouleau D SP4Rousseau Y P65Rubenstein E P66Rutherford C P50Ryding D P63

SSalmon J CVP1Sarabia A C1,P46Savchenko A P46Saxinger L A1,P1,P2,P3,P39Scalia V K2Schertzberg R SP3Schoer K C3Sealy D J2Severini A B3,P54,P60Sharma M P18,SP14Sharma N J1Shaw L P49Sheppard DC P65Shing F P7Shokoples S K1Show R B2

Simard É P17Simor A A4,D1,D3,E2,E3,E6, F2,G2,P4,P25,P34,SP29Singh C H2Sirard S SP16Skinner S SP9Small G P22Smart G P20Smart N SP14Smieja M G2,P48Smith L B2Smith S J1,J2,P9,SP6Solomon N P5Srigley J B7,P6,SP20St-Antoine P SP4St-Germain G F6St-Jean M SP23Stojios P P46St-Pierre G P17Straus K SP3Streitenberger L SP5Suh KN I3,G4Sullivan L P49Sumner J B1

TTambalo D SP24Tang P D4,G1,G3,K4,P55,P62Taruc J C4Taylor G D1,E3,G5,G6,I3, P2,P39,P42Taylor M P32Tellier R B4,P59Thampi N SP30Thanabalan R P22Thibault L P58Thirion DJG SP15,P65Thiry D P8Thliza S I4Thomas E D1,E3Tipples G P55,P56Tomalty L P26Toor R B1Toye B SP7Tsang P H1Tuite A L1Turcotte P B6Turenne C P8Turgeon N D1,E3Turnbull L P23,P27Turnbull LA P38Tyler S H2,P62Tyrrell G F4

UUlanova M L3

Authors Index


40

Proteomics, Immunoreagent Development, Animal Services, and Molecular Pathobiology.

Mark Joffe pursued undergraduate education and then medical school at the University of Calgary. He then completed training in Internal Medicine and Infectious Diseases at the University of Alberta. This was followed by a research fellowship for 3 years at Stanford University in California. Currently, he is a Professor in the Department of Medicine at the University of Alberta. His specialty practice in Infectious Diseases is based at the Royal Alexandra Hospital where he also serves as the Medical Director for the Infection Prevention and Control Program. He recently assumed the position of Senior Medical Director for Infection Prevention and Control for Alberta Health Services. In addition, he is a Staff Physician at the Edmonton Sexually Transmitted Diseases Centre and the Edmonton Institution for Women, a federal correctional facility. He is a Past-President of the Royal Alexandra Medical Staff Society and served 2 terms as President of the Capital Region Medical Staff Association. He recently completed 7 years as Chair of the Program Planning Committee of the Association of Medical Microbiology and Infectious Disease Canada and is now President-Elect of this organization. His major interests are in the prevention of infectious diseases in both patients and health care workers in acute care hospitals.

Dick Menzies received his medical training at McGill University, Montreal and specialty training in Internal Medicine at the Medical College of Pennsylvania in Philadelphia, USA. After a 2 ! year stint in Lesotho, Africa, he received further training in Respiratory Medicine and a Masters Degree in Epidemiology at McGill University. Dr. Menzies has served as Medical Director at the Montreal Chest Institute for a total of 10 years ending in 2002 and as Director of the Respiratory Epidemiology Unit at McGill University for 7 years. He is now University and Hospital Director of the Respiratory Division.

Dr. Menzies has a long history of involvement in tuberculosis care and research, beginning with his years in Lesotho, where tuberculosis is highly endemic. Since his return to Montreal, he has developed a tuberculosis research programme of clinical and epidemiologic studies linked with a large multi-disciplinary clinical service at the Montreal Chest Institute, and a group of other Montréal researchers with diverse interests and expertise in TB. He collaborates closely with the Public Health Unit of Montreal and Immigration Canada. Dr. Menzies has also been involved as a consultant to National TB Programs in the Dominican Republic,

Speaker Bios

Horacio Arruda is a specialist in Community Medicine, and has worked most extensively in the areas of infectious disease surveillance, field epidemiology, and infection prevention and control.

Since 2000, he has been a Director in the public health branch of the Ministry of Health and Social Services of Quebec, responsible for prevention and control of communicable diseases, nosocomial infections, occupational health and environmental health. He is also responsible for directing the infectious disease surveillance activities of the ministry, as well as provincial emergency planning and response.

Dr. Arruda is the coordinator of the action plan to control nosocomial infections in the province of Quebec. In the national arena, he has participated in various working groups in the Canadian Public Health network, and is the Quebec representative in the newly formed Communicable Diseases Expert Group.

Michael Drebot received his PhD in Microbiology in 1988 from Dalhousie University and was then awarded a postdoctoral fellowship in genetics from the Hospital for Sick Children (Toronto, 1988-1991). In 1991, he joined the National Centre for Enteroviruses in Halifax where he conducted research on the molecular biology of polioviruses and various enteric pathogens and was cross appointed as a professor adjunct within the Department of Microbiology and Immunology at Dalhousie University. In 1996, Dr. Drebot joined the Zoonotic Diseases program of Health Canada, Ottawa as a research scientist. In 1999, he became the Chief of Viral Zoonoses with the Zoonotic Diseases and Special Pathogens (ZDSP) section of the National Microbiology Laboratory (Winnipeg) and in 2007 took on the responsibilities of Director of the Science Technology and Core Services program. As well, Dr. Drebot is an Assistant Professor within the Medical Microbiology department, University of Manitoba and teaches a number of courses and supervises graduate students involved with various research projects.

The focus of his Viral Zoonoses program has been to work with colleagues at ZDSP on the establishment of applied and basic research programs for various zoonotic disease agents including: arboviruses (such as West Nile virus) and rodent-borne pathogens such as hantaviruses. The ZDSP program carries out reference diagnostics services, surveillance activities and a wide variety of research projects on a number of zoonotic disease agents and risk factors, geographic distribution and intervention strategies available to minimize human exposure to these pathogens. As Director of the Science Technology and Core Services he oversees a number of support/research sections that include Genomics,


41

in a number of committees for the Canadian Paediatric Society and Public Health Agency of Canada as well as Quebec provincial committees.

Howard Njoo is the Director General of the Centre for Communicable Diseases and Infection Control at the Public Health Agency of Canada. In his career as a public health physician, Dr. Njoo has worked in all three levels of government. Previously, he worked at the Public Health Branch of the Ontario Ministry of Health and as the Associate Medical Officer of Health for the City of Toronto Department of Public Health. Dr. Njoo joined the federal government in 1996 as the Director of Tuberculosis Prevention and Control at Health Canada and subsequently worked in a variety of positions, in both chronic and infectious diseases as well as emergency preparedness and response.

Dr. Njoo earned his medical degree and a Master’s in Health Science, specializing in community health and epidemiology, from the University of Toronto, and has a fellowship in the Royal College of Physicians and Surgeons of Canada in community medicine. Dr. Njoo is a Consultant Physician at the Ottawa Hospital Tuberculosis Clinic, is an Assistant Professor, Department of Medicine, Division of Infectious Diseases, and has an adjunct appointment in the Department of Epidemiology and Community Medicine at the University of Ottawa.

Astrid Petrich is the Head of Service for molecular microbiology at the Hospital for Sick Children. Her research interests include evaluating nucleic acid amplification technology to detect Influenza A and other respiratory pathogens (Rhinovirus, S. pneumoniae, human metapneumovirus) in clinical specimens from patients with respiratory disease. Her clinical service includes the optimization of molecular diagnostics for use in the clinical microbiology laboratory and the evaluation of their impact on patient care. Dr. Petrich currently has a CIHR grant with Dr. Marek Smieja to work on diagnostics for pandemic Influenza.

Dr. Petrich is the past chair and a founding member of the National Molecular Microbiology Diagnostics User’s Group (NMG), a national network of laboratorians who collaboratively work to enhance public health and hospital laboratory diagnostics in the area of molecular microbiology.

Guyana and Ecuador, and to the World Health Organization. He has published over 170 peer-reviewed papers and 25 book chapters based on the results of his research.

Mark Miller studied at McGill University in Infectious Diseases and in Medical Microbiology and then pursued a Master’s degree in Epidemiology and Biostatistics. He has been a staff microbiologist and infectious disease specialist since 1993 at the Jewish General Hospital, a McGill University-affiliated hospital, where he is the Chair of Infection Prevention and Control, the Chief of Clinical Microbiology, and the Head of Infectious Diseases. He is an Assistant Professor of Medicine and Microbiology/Immunology at McGill University.

His research focuses on the epidemiology, prevention, and treatment of healthcare-associated infections. He has described the emergence of mupirocin resistance among MRSA, chaired the cross-Canada group studying the morbidity and mortality from healthcare-associated C. difficile infection (CDI), and headed the Canadian team which surveyed the reuse of single-use medical devices. He is currently studying CDI in depth, including the recent epidemiology of severe CDI in Canada, CDI prevention and CDI therapy with novel antibiotics and immunomodulators.

He also helped establish the Quebec province-wide guidelines for physicians, dentists, and other healthcare workers infected with blood-borne diseases and is the Chairman of the Infection Control Working Group of McGill University, which harmonizes infection control policies in all McGill-affiliated health institutions. He has co-authored over 90 publications and presented over 100 abstracts. He is past-president of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada, the professional society of Canadian physicians involved in the prevention, treatment, and research in the file of Infectious Diseases. He currently lives in Montréal, Canada.

Dorothy Moore graduated from McGill with a PhD in Microbiology in 1967, Memorial University in 1977 with an MD, and trained in paediatrics and infectious diseases at the Montreal Children’s Hospital (FRSC, CSPQ, 1983; RCP Canada Certification in Infectious Diseases 1987). Dr. Moore has been a consultant in the Infectious Diseases Division of the Montréal Children’s Hospital since 1984, Infection Control Physician at the same hospital since 1984 and an Associate Professor of Paediatrics at McGill University since 1990.

Dr. Moore’s major areas of responsibility and interest include health care associated infections, paediatric HIV, vaccines, and infections in immuno-compromised patients. She is also active

Speaker Bios


42

Pathobiology. In 2001, he received the CHICA-Canada Award of Merit for service in the advancement of infection prevention and control. Dr. Simor also works as a medical volunteer at a rural hospital in Zimbabwe every one or two years, and has assisted in establishing HIV and tuberculosis treatment programs in that country.

Currently, Dr. Simor is the Chief of the Department of Microbiology and the Division of Infectious Diseases at Sunnybrook Health Sciences Centre in Toronto, along with being a Professor in the Departments of Laboratory Medicine & Pathobiology, and Medicine at the University of Toronto and the Senior Scientist at Sunnybrook Research Institute.

Réjean Thomas is the co-founder and president of l’Actuel Medical Clinic, a true pioneer in the development of HIV/AIDS knowledge and founder of Doctors of the World, Canada. Dr. Réjean Thomas has had a remarkable career that has taken him from his hometown of Tilley Road, New Brunswick, to all four corners of the world.

Dr. Thomas is a clinical practitioner at l’Actuel, a medical consultant for the Centre hospitalier universitaire de Montréal (CHUM), an associate member of the McGill University AIDS Centre and a former special advisor to the Quebec government for international humanitarian action. He helped bring humanistic medicine not only to Canada, but also abroad during several humanitarian missions to Afghanistan, Zimbabwe, Haiti, Malawi and Vietnam.

Dr. Thomas’s expertise extends to teaching, research and prevention, but especially to preserving the quality of life of patients, protecting their rights and fighting the prejudice surrounding those living with HIV/AIDS. His two-pronged approach as both a practitioner and field worker has meant that his reputation and credibility reach well beyond our borders.

Dr. Thomas is a graduate of Université de Moncton, Université Laval and Université de Montréal. He has received many awards for his exceptional work to advance social causes, including the «Hommage et Reconnaissance des médecins de coeur et d’action» award from the Association des médecins de langue française du Canada and l’Actualité médicale, and an honorary doctorate in health sciences and the Order of Merit for graduates from Université de Moncton. He has furthermore been invested as a Chevalier de l’Ordre de la Pléiade of the Assemblée parlementaire de la Francophonie and received the Farha Foundation’s Heroes Night award. He has also been invested as a Chevalier de l’Ordre national du Québec, the highest distinction given by the Quebec government.

A movie and a book document this exceptional man’s remarkable journey.

Johann Pitout is a Medical Microbiologist who completed his Medical Studies in South Africa in 1985 and qualified as a Medical Microbiologist by obtaining the FFPath (SA) degree from the College of Medicine of South Africa and M Med (Microbiol Path) from University of Stellenbosh in 1992. He then completed a postdoctoral fellowship at Dr Christine Sander’s laboratory in the Department of Medical Microbiology and Immunology, Creighton University, Omaha, Nebraska, USA. He returned to South Africa in 1996 to take a position of Consultant Microbiologist at the University of Free State and in 1999 became the Head of Medical Microbiology. He moved to the United Arab Emirates during 2000 to initiate a Diagnostic Microbiology service in Abu Dhabi. During 2001, he was offered a position as a Medical Microbiologist at Calgary Laboratory Service and Associate Professor at the University of Calgary. He was promoted to a Full Professor in 2009.

His main research interests are resistance to antimicrobial agents among Gram-negative bacteria especially the characterization and molecular epidemiology of Newer -lactamases such as AmpC, Extended-spectrum -lactamases and Carbapenem Hydrolyzing enzymes. He has also been involved in population-based surveillance studies investigating infections caused by organisms producing these newer types of -lactamases. A more recent interest is the molecular characterization of mobile elements involved in the spread and maintenance of resistance genes among Gram-negative bacteria. He has published over 80 papers in this field.

Andrew Simor graduated with a medical degree from the University of Toronto in 1976, and completed Royal College fellowship training in internal medicine, infectious diseases, and medical microbiology. He has worked at Sunnybrook Health Sciences Centre since 1993. Dr. Simor is recognized nationally and internationally as a leader in the field of hospital epidemiology. He has received research funding from peer– reviewed and industry-based granting agencies. He has published a large number of papers in scientific journals, and he is on the Editorial Board of the journal, Infection Control and Hospital Epidemiology. His primary research interests include: antimicrobial resistance, hospital-acquired infections, and the application of molecular technologies to the diagnosis and management of infectious diseases.

Dr. Simor has received several teaching awards from the university, and in 2005 was selected to receive the Distinguished Service Award for the university’s Department of Laboratory Medicine &

Speaker Bios


43

Dr Walmsley is the recipient of a career scientist award from the Ontario HIV Treatment Network and was elected as a member of the governing council of the international aids society.

Karl Weiss is a Microbiologist and Infectious Diseases Specialist as Maisonneuve-Rosemont Hospital in Montréal. He is a Professor at the Faculty of Medicine at the University of Montréal, and the director of pharmacological research at Maisonneuve-Rosemont hospital. He is also co-chairing with the Director of Public Health the Montréal infection control board. Dr. Weiss is also an associate member of the division of infectious diseases at the Jewish General Hospital in Montréal.

After receiving his doctorate from the University of Montréal, Dr. Weiss continued his studies in internal medicine at McGill University and the University of Montréal, then completed his training in infectious diseases and microbiology, where he studied new detection methods and antibiotics in the treatment of Helicobacter pylori infections.

Over the course of his career, Dr. Weiss has been a guest speaker at over 500 lectures all over the world, and has written more than 300 abstracts and journal articles for publications in journals such as The Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and Chemotherapy, the Canadian Journal of Infectious Diseases, the American Journal of Epidemiology, Clinical Infectious Diseases and Infection Control and Hospital Epidemiology. His research focuses on respiratory tract infections, antibiotics and on antimicrobial resistance.

In addition to being the President of the Québec Committee on Antibiotics and Antimicrobial Resistance, Dr. Weiss is a member of the Executive committee of several professional associations such as the Association des Médecins Microbiologistes Infectiologues du Québec. He has been a member and chaired numerous boards in Canada and at the international level, and has worked as a consultant for several governments. He was also the chairman of the examining board of the Royal College of Physicians and Surgeons of Canada for Medical Microbiology between 2002 and 2005.

Dr. Weiss received an Award of Distinction from the Association of Medical Microbiology and Infectious Disease (AMMI) Canada in 2005, and the “prix des médecins de Coeur et d’action” from l’Association des médecins de langue française du Canada in 2008.

In June 2010, Dr. Réjean Thomas was made a Member of the Order of Canada for his dedication to and work on the prevention and treatment of sexually transmitted infections and HIV/AIDS.

Cécile Tremblay is a medical microbiologist and infectious diseases specialist at Centre Hospitalier de l’Université de Montréal (CHUM),Hotel-Dieu Hospital. She is the director of the AIDS Clinical Care and Research Unit of the CHUM (UHRESS). She holds the Pfizer/University of Montreal Chair on HIV Translational Research and is associate professor in the Department of Microbiology and Immunology at the Université de Montréal. Dr Tremblay obtained her MD degree at the Université de Montréal in 1992. She then completed her residency in microbiology and infectious diseases at the same university, and thereby received her certification in medical microbiology by the Royal College of Physicians and Surgeons in Canada in 1997. She completed a post-doctorate fellowship in HIV research at Massachusetts General Hospital, under the aegis of Harvard Medical School. Dr Tremblay returned to Montreal in 2001 where, in addition to her clinical work, she directs a research laboratory that specializes in viral reservoirs, the entry of HIV into cells, as well as the emergence of antiretroviral resistance. She is involved in several clinical research projects, including HIV and premature aging and pre-clinical studies of new classes of antiretrovirals such as entry inhibitors. Her research agenda also includes HIV viral reservoirs in different contexts of immunotherapeutic manipulation as well as collaborative research in developing countries to help facilitate the medical management of HIV positive patients. Recently, she has set up a Canadian cohort of HIV positive patients known as long-term non-progressors. Research around this problem, in line with her laboratory work on the genetic evolution of the virus, could advance knowledge on the pathogenesis of HIV and could favour new approaches to the conceptualisation of vaccines and new therapies.

Sharon Walmsley is a Professor of Medicine at the University of Toronto and the Director of HIV Clinical Research at the Toronto Immunodeficiency Clinic. She was elected national chair of the Canadian HIV Trials Network and is involved in the care and management of persons living with HIV. Her clinical research focuses on the optimal use of antiretroviral agents, associated toxicity, and the special issues for women. Dr. Walmsley’s recent research is focused on the interactions between herpes simplex virus and HIV.

Speaker Bios


44

Booth # 10, 11ALERE CANADA1 - 57 Iber RoadOttawa, Ontario K2S 1E7 CanadaContact: David Smith MarketingTelephone: 613-271-1144 / 800-818-8335Fax: 613-271-1148Email: [email protected]: www.alere.caAlere Canada (formerly Inverness Medical) is a major manufacturer and supplier of diagnostic tests for the clinical laboratory. Our product offering for the microbiology and virology laboratories covers the whole spectrum from culture media, diagnostic reagents, chromogenic media, rapid diagnostics to multiplex PCR.

Booth # 54APPLIED MATHS, INC.645 - 13809 Research BoulevardAustin, Texas 78750 USATelephone: 512-482-9700Website: www.Applied-Maths.comApplied Maths develops innovative software and data management solutions for the biosciences. The company continues to be a leader in bioinformatics, with BioNumerics, GelCompar II, and GeneMaths XT.

Booth # 23ASSOCIATION OF MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASE CANADA101 – 298 Elgin StreetOttawa, Ontario K2P 1M3 CanadaContact: Brett FilsonTelephone: 613-260-3233, ext. 101Fax: 613-260-3235Email: [email protected]: www.ammi.caThe Association of Medical Microbiology and Infectious Disease (AMMI) Canada is the national association that represents physicians and researchers specializing in the fields of medical microbiology and infectious diseases. Through research, education, and partnership with other associations, AMMI Canada strives to protect people from existing and emerging infectious diseases and to provide treatment for those who are affected.

Exhibitor Directory

Booth # 13ABBOTT LABORATORIESAbbott Laboratories Ltd.Diagnostics and Molecular Divisions7115 Millcreek DriveMississauga, Ontario L5N 3R3 CanadaTelephone: 800-387-8378Fax: 905-858-2459Website: www.abbott.comAbbott products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies – addressing important health needs from infancy to the golden years.

Booth # 5ADVANCED INSTRUMENTS / SPIRAL BIOTECHTwo Technology WayNorwood, Massachusetts 02062 USAContact: Anthony Pappas National Sales ManagerTelephone: 781-320-9000 / 800-225-4034Fax: 781-320-8181Email: [email protected]: www.aicompanies.comAdvanced Instruments, Inc., a leader in the field of automated microbiology, presents the Spiral Biotech Autoplate® Spiral Plating System. Autoplate SPS features a touchscreen interface.

Booth # 44AFFINITY DIAGNOSTICS CORP.194 Wildcat RoadToronto, Ontario M3J 2N5 CanadaContact: Daniel Libertucci Managing DirectorTelephone: 416-650-6300Fax: 416-650-5990Email: [email protected]: www.affinitydiagnostics.caAFFINITY Diagnostics provides a wide variety of ELISA-based infectious disease assays and laboratory automation, allowing us to assist Canadian laboratories of all sizes. Visit our website at: www.affinitydiagnostics.ca, or call us at 1-877-370-6300.


45

Booth # 42BIO-K+ INTERNATIONAL INC.495 boulevard Armand-FrappierLaval, Québec H7V 4B3 CanadaContact: Shanti Hallard Marketing CoordinatorTelephone: 450-978-2465Fax: 450-978-9729Email: [email protected]: www.biokplus.comBio-K+ International Inc. is a research-based manufacturer specializing in clinically proven probiotics in a certified gluten-free drinkable form and as enteric-coated capsules.

Booth # 20, 21, 22BIOMÉRIEUX CANADA INC.7815, boulevard Henri-Bourassa OuestVille St-Laurent, Québec H4S 1P7 CanadaContact: François Turgeon Senior Manager Clinical MarketingTelephone: 514-336-7321, ext. 239Fax: 514-807-0015Email: [email protected]: www.biomerieux.cabioMérieux is a worldwide group specialized in the field of in vitro diagnostics for medical applications. The group designs, develops, manufactures and markets systems used in the diagnosis of infectious diseases, such as hepatitis, HIV, tuberculosis and respiratory infections, as well as pathologies such as cardiovascular diseases and cancer.

Booth # 50BIO NUCLEAR DIAGNOSTICS INC.1791 Albion RoadToronto, Ontario M9W 5S7 CanadaContact: Gerald Blackwell Manager, Diagnostics & Regulatory AffairsTelephone: 416-674-1545 / 800-668-4033Fax: 416-674-7280Email: [email protected]: www.bndinc.comBio Nuclear introduces the innovative 3M™ Integrated Cycler and an expanding menu of Simplexa™ assays as real-time solutions for your clinical laboratory`s molecular needs.

Booth # 1ASTELLAS PHARMA CANADA, INC.500 - 675 Cochrane Drive, West TowerMarkham, Ontario L3R 0B8 CanadaContact: Jonathan Lambert Product Manager, Critical CareTelephone: 905-946-5624Fax: 905-470-2538Email: [email protected]: www.astellas.comAstellas Pharma Canada, Inc., a Canadian affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world. In Canada, Astellas focuses on five key therapeutic areas – Immunology, Urology, Cardiology, Dermatology and Infectious Disease. For more information, please visit www.astellas.com/ca.

Booth # 32BAYER INC.77 Belfield RoadToronto, Ontario M9W 1G6 CanadaContact: Katie Derbyshire Market Manager Avelox/Avelox IVTelephone: 416-240-5234Cell: 647-938-4600Website: www.bayer.caBayer Inc. is a Canadian subsidiary of Bayer AG, an international research-based group with core businesses in health care, crop science and innovative materials.

Booth # 65, 66BD DIAGNOSTICSWebsite: www.bd.comBD Diagnostics is a leading provider of products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems to accurately detect a broad range of infectious diseases, healthcare-associated infections (HAIs) and cancers. BD Diagnostics focuses on improving health outcomes for patients and providing laboratories with solutions that improve quality, enhance laboratory system productivity, reduce costs and inform medical decisions.

Exhibitor Directory


46

Booth # 25CANADIAN ASSOCIATION FOR CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASESc/o National Microbiology Laboratory 1015 Arlington Street Winnipeg, Manitoba R3E 3R2 CanadaContact: Dr. Matthew Gilmour Telephone: 204-784-5920 Fax: 204-789-5012 Email: [email protected] Website: www.cacmid.ca

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) is one of Canada’s longest-standing microbiology associations, and our mission is to actively promote the cooperation, collaborative research, and education amongst microbiologists. Please visit the CACMID booth to learn about the benefits of membership and the activities of CACMID. Technician members can pick up their application forms for educational travel grants.

Booth # 26CANADIAN COLLEGE OF MICROBIOLOGISTSc/o Saskatchewan Disease Control Laboratory5 Research DriveRegina, Saskatchewan S4S 0A4 CanadaContact: Dr. Paul N. Levett President, CCMTelephone: 306-787-3135Email: [email protected]: www.ccm.caThe Canadian College of Microbiologists (CCM) is a professional association for Microbiologists across Canada. It operates with legal and professional status as a non-profit organization serving Canada certifying professional microbiologists (RMCCM, SCCM, ARMCCM, and FCCM) who have demonstrated proficiency, knowledge, and experience within their discipline.

Booth # 29CANADIAN INSTITUTES OF HEALTH RESEARCH – INSTITUTE OF INFECTION AND IMMUNITY2705 boulevard Laurier, TR-100Québec, Québec G1V 4G2 CanadaTelephone: 418-577-4688Fax: 418-577-4689Website: http://www.cihr.gc.ca/e/13533.html

The Canadian Institutes of Health Research (CIHR) is the Government of Canada’s agency responsible for funding health research in Canada.

Booth # 51BIO-RAD LABORATORIES2403 GuénetteMontréal, Québec H4R 2E9 CanadaContact: Louis Beaudoin National Sales ManagerTelephone: 514-334-4372Fax: 514-334-4415Email: [email protected] Laboratories is one of the biggest leading diagnostics companies worldwide. It is recognized for its leadership position in quality controls, diabetes monitoring, autoimmune diseases and microbiology.

Booth # 36BRISTOL-MYERS SQUIBB CANADA CO.2344 Alfred-NobelSt-Laurent, Québec H4S 0A4 CanadaContact: Medical InformationTelephone: 866-463-6267Fax: 888-267-6211Email: [email protected]: www.bmscanada.caBristol-Myers Squibb Company’s Mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products.

Booth # 4BRUKER LTD.40 Manning RoadBillerica, Massachusetts 01821 USAContact: Angela Abraham Applications Technologist 555 Steeles Avenue East Milton, Ontario L9T 1Y6 CanadaTelephone: 905-876-4641, ext. 107Fax: 905-876-4421Email: [email protected]: www.bdal.comBruker Ltd. is the leading provider of mass spectrometry instruments for the analytical sciences. The industry leading MALDI Biotyper produces identifications in minutes for a broad range of bacteria and yeast with minimal reagents from primary culture.

Exhibitor Directory


47

Booth # 12COPAN DIAGNOSTICS, INC.26055 Jefferson Avenue, Murrieta, California 92562 USAContact: Norman SharplesTelephone: 951-696-6957 / 800-216-4016Fax: 951-600-1832 Email: [email protected]: www.copanusa.comWith a reputation for innovation in preanalytics, COPAN is the leading manufacturer of collection and transport systems. Flocked Swabs, Universal Transport Medium, WASP and ESwab.

Booth # 27DAAN DIAGNOSTICS LTD.200 - 5050 Kingsway, Burnaby, British Columbia V5H 4H2 CanadaContact: Selena Wang Product SpecialistTelephone: 604-451-7588Fax: 604-451-7587Email: [email protected]: www.daandiagnostics.comDaan Diagnostics specializes in development of real time PCR reagents and kits for detection of infectious agents.

Booth # 19DIASORIN INC.730 - 5915 Airport Road, Mississauga, Ontario L4V 1T1 CanadaContact: Gina Franky Country ManagerTelephone: 905-677-1600Fax: 905-677-1630Email: [email protected]: diasorin.comDiaSorin, the Diagnostic Specialist, provides specialized reagents and automated diagnostic instrumentation for laboratories. DiaSorin offers immunodiagnostic assays for infectious disease, autoimmune, bone and endocrine diseases.

Booth # 64EUROIMMUN CANADA36 - 1100 Central Parkway West Mississauga, Ontario L5C 4E5 CanadaContact: Donglai Ma DirectorTelephone: 905-896-1504Fax: 905-896-1506Email: [email protected]: www.euroimmun.caEUROIMMUN produces and distributes high quality medical diag-nostics reagents for infectious diseases, autoimmune diseases and allergies, which are used in more than 3000 laboratories worldwide.

Booth # 3CANADIAN PUBLIC HEALTH LABORATORY NETWORK (CPHLN)1015 Arlington StreetWinnipeg, Manitoba R3H 1H2 CanadaEmail: [email protected]: CPHLN.ca or RLSPC.caThe CPHLN is a national association of public health laboratory professionals that acts as a unified voice for federal and provincial member laboratories.

Booth # 67CANADIAN SOCIETY FOR MEDICAL LABORATORY SCIENCE (CSMLS) LEARNING SERVICESPO/CP 2830, LCD 1/PDF 1Hamilton, Ontario L8N 3N8 CanadaContact: Michele Perry Team Leader, Learning ServicesTelephone: 800-263-8277, ext. 8680Fax: 905-528-4968Email: [email protected]: www.csmls.orgCSMLS is the national certifying body for medical laboratory technologists and medical laboratory assistants, and the national professional society for Canada’s medical laboratory professionals. CSMLS Learning Services offers over 100 courses designed particularly for medical laboratory professionals.

Booth # 35CEDARLANE CORPORATION4410 Paletta CourtBurlington, Ontario L7L 5R2 CanadaContact: Eddie Johnson General ManagerTelephone: 289-288-0001Fax: 289-288-0020Email: [email protected]: www.cedarlanelabs.comCEDARLANE® specializes in providing quality research and diagnostic reagents to the life science community, including products from ATCC, Millipore/Chemicon, Immunetics and Astra Diagnostics.

Exhibitor Directory


48

Booth # 52INNOVATEK MEDICAL INC.3 - 1600 Derwent WayDelta, British Columbia V3M 6M5 CanadaContact: Marcus Titian Parsad National Sales ManagerTelephone: 604-522-8303Fax: 604-522-8318Email: [email protected]: www.innovatekmed.com

Innovatek Medical has a focus on clinical laboratory technology, represents diagnostic kits for women’s health, drugs of abuse and infectious diseases.

Booth # 33INTER MEDICO50 Valleywood DriveMarkham, Ontario L3R 6E9 CanadaContact: Carrie Ebenhardt Vice-President Sales & MarketingTelephone: 800-387-9643Fax: 905-470-2381Email: [email protected]: www.inter-medico.comInter Medico provides automated technology solutions for rapid bacterial culture analysis and infection control molecular testing such as MRSA, VRE and C.difficile.

Booth # 58ISENTIO US440 North Wolfe Drive, Sunnyvale, California 94085 USAContact: Bjarte Karlsen PresidentU.S. Cell: 408-636-8951Norway Cell: 0047 982 19 588Email: [email protected]: www.isentio.com www.ripseq.comThe iSentio RipSeq® online application enables direct sequencing from poly-microbial samples. This reduces identification time by 50 90% by eliminating the need for cultivation prior to sequencing.

Booth # 7, 8, 9GEN-PROBE10210 Genetic Center DriveSan Diego, California 92121 USAContact: Cynthia DeMent Sr. Tradeshow & MarCom CoordinatorTelephone: 858-410-8996Fax: 858-410-7815Email: [email protected]: www.gen-probe.comGen-Probe is a global leader in molecular diagnostics for infectious disease, blood screening, oncology and transplant diagnostics. Gen-Probe manufactures and markets rapid, accurate and cost-effective nucleic acid tests (NATs) and fully automated instruments to provide a broad range of technologies that support women’s health and detect infectious microorganisms, including those causing sexually transmitted diseases (STDs), respiratory infectious diseases, C. diff., tuberculosis, strep throat, pneumonia and fungal infections.

Booth # 60i2a CANADA1699, chemin 8e rangVal David, Québec J0T 2N0 CanadaContact: Pierre Lacroix General ManagerTelephone: 514-910-8051Email: [email protected]: www.i2a.infoi2a manufactures and markets SirScan automated susceptibility readers, middleware data management (Sirweb-Maldi, Universal expert system, epidemiology/infection control software). Exclusive Canadian distributor of Biotyper TBD.

Booth # 61INFECTIOUS DISEASES SOCIETY OF AMERICA (IDSA)300 - 1300 Wilson BoulevardArlington, Virginia 22209 USAContact: John Buckley Director, Meeting ServicesTelephone: 703-299-0200Fax: 866-579-0939Email: [email protected]: www.idsociety.orgIDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.

Exhibitor Directory


49

Booth # 30NATIONAL MICROBIOLOGY LABORATORYNational Microbiology LaboratoryPublic Health Agency of Canada1015 Arlington Street, Winnipeg, Manitoba R3E 3R2 CanadaContact: Sabrina A. Choma Manager, Technology Transfer Office of Intellectual Property Management & Business DevelopmentTelephone: 204-789-2120Fax: 204-789-2097Email: [email protected], Canada’s only BSL4 containment laboratory, is a leading public health infectious disease research centre, responsible for the identification, control and prevention of infectious diseases.

Booth # 62NOSOTECH INC.125, rue de l’Évêché OuestRimouski, Québec G5L 4H4 CanadaTelephone: 418-723-0862Fax: 418-722-8556Website: nosotech.comContact: Mario Brisson Directeur général [email protected] has designed a modern software that provides all the tools necessary for healthcare-associated infections surveillance. Nosokos™ enables infection control and prevention professionals to follow, manage and decrease nosocomial infection rates in healthcare settings.

Booth # 34, 43NOVARTIS PHARMACEUTICALS CANADA INC.Contact: Greig EstabrooksTelephone: 514-631-6775, ext. 1095Email: [email protected] is the world’s fifth largest manufacturer of vaccines and the second largest producer of influenza vaccine. We are dedicated to delivering on the promise of prevention through research, development and production of innovative, safe and effective vaccines.At Novartis, caring begins with prevention.

Booth # 31LABSPHERE INC.108 - 3900 Place de JavaBrossard, Québec J4Y 0C4 CanadaContact: Tony D’Antico PresidentTelephone: 450-444-0085Fax: 450-444-2537Email: [email protected]: www.labsphere.bizDistribution of:• MIDI systems and consumables• Chromatographic and biological consumables• CTC/PAL instrumentation, accessories and partsServices:• Preventative Maintenance• Instrument Qualification• Training and Courses• Service Agreements

Booth # 28LAROSE ET FILS LTÉEContact: André Foisy Director of developmentTelephone: 877-382-7001Website: www.larose.caCleaning to prevent the spread of antibiotic resistant bacteria. Presentation of a preferred cleaning approach for health care facilities with a validated cleaning process.

Booth # 45, 53MERCKWebsite: www.merck.caToday’s Merck is a global healthcare leader working to help the world be well. For more information, visit www.merck.ca.

Booth # 2NATIONAL COLLABORATING CENTRE FOR INFECTIOUS DISEASES (NCCID)413 - 445 Ellice Avenue, Winnipeg, Manitoba R3B 3P5 CanadaContact: Renée Barclay Communications CoordinatorTelephone: 204-943-0051Fax: 204-946-0927Email: [email protected]: http://nccid.caNCCID works with public health practitioners to identify gaps in knowledge, synthesize and disseminate the latest ID research and tools, and provide forums for collaboration.

Exhibitor Directory


50

Booth # 24PULSUS GROUP2902 South Sheridan Way, Oakville, Ontario L6J 7L6 CanadaContact: Ann LeBlanc Vice PresidentTelephone: 905-829-4770Fax: 905-829-4799Email: [email protected]: www.pulsus.comPulsus Group is a Canadian publishing company specializing in high quality, peer review medical journals including The Canadian Journal of Infectious Diseases & Medical Microbiology.

Booth # 55PURITAN MEDICAL PRODUCTS CO. LLC31 School Street, Guilford, Maine 04443 USAContact: Timothy Templet Executive V. P. of SalesTelephone: 207-876-3311, ext. 3233Fax: 207-876-3130Email: [email protected]: www.puritanmedproducts.comNorth America’s leading manufacturer of quality medical and diagnostic products, specializing in specimen collection: Patent-pending HydraFlock and PurFlock Ultra for superior collection/release, cotton, polyester, and foam-tipped applicators.

Booth # 63QIAGEN, INC.19300 Germantown Road, Germantown, Maryland 20874 USAContact: Ronald M. Kolojek Area Business Director – CanadaTelephone: 800-426-8157, ext. 22152Cell: 440-279-3734Fax: 661-702-3853Email: [email protected]: www.qiagen.comQIAGEN is the leading provider of sample and assay technologies, and provides these products to molecular diagnostics laboratories and laboratories focusing on molecular based results.

Booth # 56, 57ROCHE, DIVISION OF HOFFMANN-LA ROCHE LIMITEDApplied Science and Molecular Diagnostics201 Armand-Frappier BoulevardLaval, Québec H7V 4A2 CanadaContact: Breanne Weismann Marketing Manager, Molecular DiagnosticsTelephone: 450-686-3093Fax: 450-686-7012Email: [email protected]: www.rochediagnostics.com

Booth # 47ORTHO CLINICAL DIAGNOSTICSOrtho Clinical DiagnosticsA Johnson & Johnson company200 Whitehall DriveMarkham, Ontario L3R 0T5 CanadaContact: Sean Chaudhry Director of MarketingEmail: [email protected]: orthoclinical.comOrtho Clinical Diagnostics, a Johnson & Johnson company, is a leading provider of high-value diagnostic products and services for the global health care community.

Booth # 14, 15OXOID, PART OF THERMO FISHER SCIENTIFIC100 - 1926 Merivale Road, Nepean, Ontario K2G 1E8 CanadaTelephone: 800-267-6391Email: [email protected] and Remel brands, trusted for high quality products, service, and support, are evolving to bring the microbiology market more innovation. From sample collection through identification, we have products to fit your work flow.

Booth # 16, 17 and 37, 38, 39, 40PFIZER CANADA INC.Website: www.pfizer.caPfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world’s leading biopharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer Inc. invests more than US$7 billion annually in R&D to discover and develop innovative life-saving and life-enhancing medicines in a wide range of therapeutic areas. Our diversified health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.

Booth # 18PHOENIX AIRMID BIOMEDICAL1166 South Service Road West, Oakville, Ontario L6L 5T7 CanadaContact: Aldo Covelli Director of Sales and MarketingTelephone: 905-469-4253Fax: 905-825-9795Email: [email protected]: phoenixairmid.comPhoenix AirMid Biomedical distributes a wide range of excellent quality autoimmune, infectious disease, and molecular diagnostic products. We also provide experience in adapting these products to automated platforms.

Exhibitor Directory


51

Booth # 48, 49SIEMENS HEALTHCARE DIAGNOSTICS LTD.1200 Courtney Park Drive EastMississauga, Ontario L5T 1P2 CanadaContact: Adelina Badiali Marketing Co-ordinatorTelephone: 905-795-4521Email: [email protected]: www.siemens.com/diagnosticsSiemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance-driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes.

Booth # 6SOMAGEN DIAGNOSTICS INC.9220 - 25 AvenueEdmonton, Alberta T6N 1E1 CanadaContact: Jaylene Lavoie Director of MarketingTelephone: 800-661-9993Fax: 780-438-6595Website: www.somagen.comAs Canada’s leading Diagnostics distribution company, we represent products that are market leaders in a complex and evolving Health Care environment.

Booth # 46STARPLEX SCIENTIFIC INC.50A Steinway BoulevardEtobicoke, Ontario M9W 6Y3 CanadaContact: Susan Finn Product Manager, Technical SpecialistTelephone: 416-674-7474Fax: 416-675-6636Email: [email protected]: www.starplexscientific.comStarplex Scientific Inc. specializes in premium quality, innovation devices for specimen collection and transportation; featuring Leakbuster 3 with tri-sensory capping technology and a full range of media swabs.

Professional Diagnostics201 Armand-Frappier BoulevardLaval, Québec H7V 4A2 CanadaContact: Marie-Josée Dupuis Marketing Manager, Reagents, Professional DiagnosticsTelephone: 450-686-3118Fax: 450-973-3974Email: [email protected]: www.rochediagnostics.comPharma2455 Meadowpine BoulevardMississauga, Ontario L5N 6L7 CanadaContact: Henry Zheng Marketing AssociateTelephone: 905-542-5555, ext. 4549Fax: 905-542-5502Email: [email protected]: www.rochediagnostics.comRoche is a leader in the research and development of pharmaceutical and diagnostic solutions that look beyond today’s horizons and make a profound difference in people’s lives.

Booth # 41SEPRACOR PHARMACEUTICALS, INC.100 - 6790 Century AvenueMississauga, Ontario L5N 2V8 CanadaContact: Arlene McCarthy CUBICIN Business ManagerTelephone: 866-260-6291Fax: 905-363-0162Email: [email protected]: www.sepracorpharma.caSepracor Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of prescription products in Canada. We specialize in treatments to help people with cardiovascular disease, infectious disease, CNS, psychiatry and pain.

Booth # 59SHELDON MANUFACTURING, INC.300 North 26th AvenueCornelius, Oregon 97113 USAContact: Jeff Boileau International Sales ManagerTelephone: 503-640-3000Fax: 503-640-1366Email: [email protected]: www.shellab.comManufacturer of high quality, SHEL LAB constant temperature and environmental control equipment, incubators, ovens, chambers and water baths.

Exhibitor Directory


52

EXHIBITING COMPANY NAME BOOTH NUMBERBruker Ltd. 4Canadian Association for Clinical Microbiology and Infectious Diseases 25Canadian College of Microbiologists (CCM) 26Canadian Institutes of Health Research – Institute of Infection and Immunity 29Canadian Public Health Laboratory Network (CPHLN) 3Canadian Society for Medical Laboratory Science (CSMLS) Learning Services 67Cedarlane Corporation 35Copan Diagnostics, Inc. 12Daan Diagnostics Ltd. 27DiaSorin Inc. 19EUROIMMUN Canada 64

EXHIBITING COMPANY NAME BOOTH NUMBERAbbott Laboratories 13Advanced Instruments / Spiral Biotech 5AFFINITY Diagnostics Corp. 44Alere Canada 10,11Applied Maths, Inc. 54Association of Medical Microbiology and Infectious Disease Canada 23Astellas Pharma Canada Inc. 1Bayer Inc. 32BD Diagnostics 65, 66Bio-K+ International Inc. 42bioMérieux Canada, Inc. 20, 21, 22Bio Nuclear Diagnostics Inc. 50Bio-Rad Laboratories 51Bristol-Myers Squibb Canada Co. 36

Exhibition Overview


53

EXHIBITING COMPANY NAME BOOTH NUMBEROrtho Clinical Diagnostics 47Oxoid, Part of Thermo Fisher Scientific 14, 15Pfizer Canada Inc. 16,17 and 37, 38, 39, 40Phoenix AirMid Biomedical 18Pulsus Group 24Puritan Medical Products Co. LLC 55QIAGEN, Inc. 63Roche, Division of Hoffmann-La Roche Limited 56, 57Sepracor Pharmaceuticals, Inc. 41Sheldon Manufacturing, Inc. 59Siemens Healthcare Diagnostics Ltd. 48, 49Somagen Diagnostics Inc. 6Starplex Scientific Inc. 46

EXHIBITING COMPANY NAME BOOTH NUMBERGen-Probe 7, 8, 9i2a Canada 60Infectious Diseases Society of America (IDSA) 61Innovatek Medical Inc. 52Inter Medico 33iSentio US 58Lab Sphere Inc. 31Larose et Fils Ltée 28Merck 45, 53National Collaborating Centre for Infectious Diseases (NCCID) 2National Microbiology Laboratory 30Nosotech inc. 62Novartis Pharmaceuticals Canada Inc. 34, 43

Exhibition Overview


54

GRANDE PLACE

RAMEZAY VIGER PALAIS BEAVERHALL

STE-HÉLÈNE McGILLST-P

AUL

LE M

OYN

E

CLO

AKR

OO

M

STORAGE

MEC

HA

NIC

AL

3rd Floor

8th Floor

Floor Plans


55

9th Floor

11th Floor

Floor Plans


56Sponsors

Platinum

Bronze

Copper

Patron

Final Program Programme final - CACMID...Riccarda Galioto M EETING PLANNER Gregory Tyrrell PRESIDENT CPC C O-C HAIR Heather Adam VICE PRESIDENT SCIENTIFI C PLANNING COMM ITTEE CO-C

Documents